AU5268800A - Genetic modification of male germ cells for generation of transgenic species and genetic therapies - Google Patents
Genetic modification of male germ cells for generation of transgenic species and genetic therapies Download PDFInfo
- Publication number
- AU5268800A AU5268800A AU52688/00A AU5268800A AU5268800A AU 5268800 A AU5268800 A AU 5268800A AU 52688/00 A AU52688/00 A AU 52688/00A AU 5268800 A AU5268800 A AU 5268800A AU 5268800 A AU5268800 A AU 5268800A
- Authority
- AU
- Australia
- Prior art keywords
- vertebrate
- cell
- male
- transgenic
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000009261 transgenic effect Effects 0.000 title claims description 139
- 210000003794 male germ cell Anatomy 0.000 title claims description 75
- 238000012239 gene modification Methods 0.000 title description 13
- 230000005017 genetic modification Effects 0.000 title description 13
- 235000013617 genetically modified food Nutrition 0.000 title description 13
- 230000002068 genetic effect Effects 0.000 title description 10
- 238000002560 therapeutic procedure Methods 0.000 title description 5
- 210000004027 cell Anatomy 0.000 claims description 173
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 163
- 238000000034 method Methods 0.000 claims description 149
- 108090000623 proteins and genes Proteins 0.000 claims description 147
- 210000001550 testis Anatomy 0.000 claims description 137
- 210000004602 germ cell Anatomy 0.000 claims description 76
- 102000004169 proteins and genes Human genes 0.000 claims description 62
- 108091033319 polynucleotide Proteins 0.000 claims description 60
- 102000040430 polynucleotide Human genes 0.000 claims description 60
- 239000002157 polynucleotide Substances 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 58
- 108020004414 DNA Proteins 0.000 claims description 56
- 238000001727 in vivo Methods 0.000 claims description 54
- 230000014509 gene expression Effects 0.000 claims description 52
- 238000000338 in vitro Methods 0.000 claims description 51
- 238000001476 gene delivery Methods 0.000 claims description 50
- 241000699670 Mus sp. Species 0.000 claims description 47
- 239000013598 vector Substances 0.000 claims description 46
- 210000001519 tissue Anatomy 0.000 claims description 37
- 210000002863 seminiferous tubule Anatomy 0.000 claims description 34
- 241000894007 species Species 0.000 claims description 26
- 239000003550 marker Substances 0.000 claims description 24
- 238000012248 genetic selection Methods 0.000 claims description 23
- 238000002347 injection Methods 0.000 claims description 23
- 239000007924 injection Substances 0.000 claims description 23
- 210000000130 stem cell Anatomy 0.000 claims description 21
- 241000700159 Rattus Species 0.000 claims description 19
- 239000002243 precursor Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 16
- 230000001177 retroviral effect Effects 0.000 claims description 15
- 239000013603 viral vector Substances 0.000 claims description 15
- 238000009395 breeding Methods 0.000 claims description 14
- 230000001488 breeding effect Effects 0.000 claims description 14
- 210000001082 somatic cell Anatomy 0.000 claims description 13
- 241000283690 Bos taurus Species 0.000 claims description 12
- 229920000656 polylysine Polymers 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 11
- 230000013011 mating Effects 0.000 claims description 10
- 230000004720 fertilization Effects 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 9
- 210000000582 semen Anatomy 0.000 claims description 9
- 210000000717 sertoli cell Anatomy 0.000 claims description 9
- 241000272517 Anseriformes Species 0.000 claims description 8
- 241000286209 Phasianidae Species 0.000 claims description 8
- 230000009027 insemination Effects 0.000 claims description 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 7
- 230000012470 leptotene Effects 0.000 claims description 7
- 210000004681 ovum Anatomy 0.000 claims description 7
- 230000010765 pachytene Effects 0.000 claims description 7
- 230000009353 zygotene Effects 0.000 claims description 7
- 108050006400 Cyclin Proteins 0.000 claims description 6
- 102000016736 Cyclin Human genes 0.000 claims description 6
- 102000002322 Egg Proteins Human genes 0.000 claims description 6
- 108010000912 Egg Proteins Proteins 0.000 claims description 6
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000002103 transcriptional effect Effects 0.000 claims description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 5
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims description 5
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims description 5
- 241000283153 Cetacea Species 0.000 claims description 4
- 241000272201 Columbiformes Species 0.000 claims description 4
- 241000699800 Cricetinae Species 0.000 claims description 4
- 241000271559 Dromaiidae Species 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 4
- 241000287828 Gallus gallus Species 0.000 claims description 4
- 241000699694 Gerbillinae Species 0.000 claims description 4
- 241000272458 Numididae Species 0.000 claims description 4
- 241000271567 Struthioniformes Species 0.000 claims description 4
- 241000282898 Sus scrofa Species 0.000 claims description 4
- 235000013330 chicken meat Nutrition 0.000 claims description 4
- 210000000805 cytoplasm Anatomy 0.000 claims description 4
- 238000002224 dissection Methods 0.000 claims description 4
- 102000034287 fluorescent proteins Human genes 0.000 claims description 4
- 108091006047 fluorescent proteins Proteins 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 108091026890 Coding region Proteins 0.000 claims description 3
- 102100032510 Heat shock protein HSP 90-beta Human genes 0.000 claims description 3
- 101001016856 Homo sapiens Heat shock protein HSP 90-beta Proteins 0.000 claims description 3
- 101000988090 Leishmania donovani Heat shock protein 83 Proteins 0.000 claims description 3
- 102000015215 Stem Cell Factor Human genes 0.000 claims description 3
- 108010039445 Stem Cell Factor Proteins 0.000 claims description 3
- 101150042435 Xrcc1 gene Proteins 0.000 claims description 3
- 230000036760 body temperature Effects 0.000 claims description 2
- 210000002332 leydig cell Anatomy 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 241000282465 Canis Species 0.000 claims 3
- 241000282324 Felis Species 0.000 claims 3
- 208000005647 Mumps Diseases 0.000 claims 1
- 208000010805 mumps infectious disease Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 76
- 238000011282 treatment Methods 0.000 description 56
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 51
- 229960002092 busulfan Drugs 0.000 description 46
- 238000012360 testing method Methods 0.000 description 41
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 38
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 38
- 239000005090 green fluorescent protein Substances 0.000 description 38
- 210000005239 tubule Anatomy 0.000 description 34
- 239000000047 product Substances 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 238000001890 transfection Methods 0.000 description 26
- 239000002245 particle Substances 0.000 description 24
- 238000010361 transduction Methods 0.000 description 20
- 230000026683 transduction Effects 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 238000005516 engineering process Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 230000002381 testicular Effects 0.000 description 16
- 241000701161 unidentified adenovirus Species 0.000 description 16
- 230000021595 spermatogenesis Effects 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 235000013601 eggs Nutrition 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 229940100198 alkylating agent Drugs 0.000 description 12
- 239000002168 alkylating agent Substances 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 238000012512 characterization method Methods 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 239000005089 Luciferase Substances 0.000 description 10
- 108700019146 Transgenes Proteins 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 210000002257 embryonic structure Anatomy 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 108060001084 Luciferase Proteins 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 9
- 238000001415 gene therapy Methods 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 108700008625 Reporter Genes Proteins 0.000 description 8
- 210000001612 chondrocyte Anatomy 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 230000010354 integration Effects 0.000 description 8
- 238000000520 microinjection Methods 0.000 description 8
- 230000005855 radiation Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 208000000509 infertility Diseases 0.000 description 6
- 230000036512 infertility Effects 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- -1 promoters Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 102100020948 Growth hormone receptor Human genes 0.000 description 5
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 5
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 230000000920 spermatogeneic effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 229950004616 tribromoethanol Drugs 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 4
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 4
- 108091029865 Exogenous DNA Proteins 0.000 description 4
- 101000915402 Homo sapiens Deleted in azoospermia protein 1 Proteins 0.000 description 4
- 102100034349 Integrase Human genes 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 102000055460 human DAZ1 Human genes 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000001638 lipofection Methods 0.000 description 4
- 230000021121 meiosis Effects 0.000 description 4
- 229940090009 myleran Drugs 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 210000002830 rete testis Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 3
- 102000003847 Carboxypeptidase B2 Human genes 0.000 description 3
- 108010022510 Collagen Type X Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 208000007466 Male Infertility Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000714177 Murine leukemia virus Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 108010053210 Phycocyanin Proteins 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 102100038803 Somatotropin Human genes 0.000 description 3
- 108010068542 Somatotropin Receptors Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 3
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 206010003883 azoospermia Diseases 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 108091005948 blue fluorescent proteins Proteins 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 210000002149 gonad Anatomy 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000021267 infertility disease Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000002406 microsurgery Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000004660 morphological change Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 210000003101 oviduct Anatomy 0.000 description 3
- 108060006184 phycobiliprotein Proteins 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 210000005000 reproductive tract Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 3
- 210000001325 yolk sac Anatomy 0.000 description 3
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 2
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 102100029136 Collagen alpha-1(II) chain Human genes 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000771163 Homo sapiens Collagen alpha-1(II) chain Proteins 0.000 description 2
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 description 2
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 2
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102000006830 Luminescent Proteins Human genes 0.000 description 2
- 108010047357 Luminescent Proteins Proteins 0.000 description 2
- 101710195116 Melanoma-derived growth regulatory protein Proteins 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 102100034670 Myb-related protein B Human genes 0.000 description 2
- 101710115153 Myb-related protein B Proteins 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000004067 Osteocalcin Human genes 0.000 description 2
- 108090000573 Osteocalcin Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102000007238 Transferrin Receptors Human genes 0.000 description 2
- 108010033576 Transferrin Receptors Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 108010041089 apoaequorin Proteins 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- BRXCDHOLJPJLLT-UHFFFAOYSA-N butane-2-sulfonic acid Chemical compound CCC(C)S(O)(=O)=O BRXCDHOLJPJLLT-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000003809 male germ line stem cell Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008627 meiotic prophase Effects 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 231100000527 sperm abnormality Toxicity 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- LAGUSEHJTGJJRJ-UHFFFAOYSA-N 2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)-2-oxoethyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(C(=O)CNC(=O)C(CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC LAGUSEHJTGJJRJ-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- 101150055869 25 gene Proteins 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 241001455214 Acinonyx jubatus Species 0.000 description 1
- 102100036601 Aggrecan core protein Human genes 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101001075278 Bos taurus Growth hormone receptor Proteins 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108090000943 Cholesterol 7-alpha-monooxygenases Proteins 0.000 description 1
- 102000004410 Cholesterol 7-alpha-monooxygenases Human genes 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000030746 Collagen Type X Human genes 0.000 description 1
- 102100040512 Collagen alpha-1(IX) chain Human genes 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102100038637 Cytochrome P450 7A1 Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 108700003861 Dominant Genes Proteins 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 102000017694 GABRA3 Human genes 0.000 description 1
- 101150035834 GABRA3 gene Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241001466538 Gymnogyps Species 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 102000006754 Hepatocyte Nuclear Factor 1 Human genes 0.000 description 1
- 108010086512 Hepatocyte Nuclear Factor 1 Proteins 0.000 description 1
- 102000009824 Hepatocyte Nuclear Factor 1-alpha Human genes 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 1
- 101000946518 Homo sapiens Carboxypeptidase B2 Proteins 0.000 description 1
- 101000725508 Homo sapiens Cartilage oligomeric matrix protein Proteins 0.000 description 1
- 101000749901 Homo sapiens Collagen alpha-1(IX) chain Proteins 0.000 description 1
- 101000893321 Homo sapiens Gamma-aminobutyric acid receptor subunit alpha-3 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 101000616502 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Proteins 0.000 description 1
- 101000688606 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 Proteins 0.000 description 1
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- 230000035986 JAK-STAT signaling Effects 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 101150118570 Msx2 gene Proteins 0.000 description 1
- 101000725510 Mus musculus Cartilage oligomeric matrix protein Proteins 0.000 description 1
- 101100256871 Mus musculus Inppl1 gene Proteins 0.000 description 1
- 101000973512 Mus musculus Melanoma-derived growth regulatory protein Proteins 0.000 description 1
- 101100096242 Mus musculus Sox9 gene Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 102100021797 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Human genes 0.000 description 1
- 102100024242 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 Human genes 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108010044068 Polyomavirus Transforming Antigens Proteins 0.000 description 1
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 101100440915 Rattus norvegicus Cyp7a1 gene Proteins 0.000 description 1
- 101000983304 Rattus norvegicus Osteocalcin Proteins 0.000 description 1
- 108700005079 Recessive Genes Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101150106167 SOX9 gene Proteins 0.000 description 1
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010051872 Testicular injury Diseases 0.000 description 1
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000030120 acrosome reaction Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000569 acute exposure Toxicity 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- HODFCFXCOMKRCG-UHFFFAOYSA-N bitolterol mesylate Chemical compound CS([O-])(=O)=O.C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)C[NH2+]C(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 HODFCFXCOMKRCG-UHFFFAOYSA-N 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-YCVQJEHTSA-N bryostatins Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)C([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-YCVQJEHTSA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000005973 campomelic dysplasia Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000009391 cell specific gene expression Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000027326 copulation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 210000001257 corticotroph Anatomy 0.000 description 1
- 230000003131 corticotrophic effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 108010005905 delta-hGHR Proteins 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- AATGCJGOPIYTKU-UHFFFAOYSA-M ethyl-hexadecyl-dihydroxyazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](O)(O)CC AATGCJGOPIYTKU-UHFFFAOYSA-M 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004420 female germ cell Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003783 haploid cell Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 208000008634 oligospermia Diseases 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 108090000629 orphan nuclear receptors Proteins 0.000 description 1
- 102000004164 orphan nuclear receptors Human genes 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009396 radiation induced apoptosis Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 231100000091 reproductive toxicant Toxicity 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000001764 somatotrope Anatomy 0.000 description 1
- 230000008010 sperm capacitation Effects 0.000 description 1
- 210000004336 spermatogonium Anatomy 0.000 description 1
- 231100000081 spermatotoxicity Toxicity 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 210000003670 sublingual gland Anatomy 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- PYIHTIJNCRKDBV-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCC[N+](C)(C)C PYIHTIJNCRKDBV-UHFFFAOYSA-L 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/061—Sperm cells, spermatogonia
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Environmental Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Obesity (AREA)
Description
WO 00/69257 PCT/USOO/13000 1 GENETIC MODIFICATION OF MALE GERM CELLS FOR GENERATION OF TRANSGENIC SPECIES & GENETIC THERAPIES BACKGROUND OF THE INVENTION 5 Throughout this application various publications are referenced within parentheses. The disclosures of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains. 1. THE FIELD OF THE INVENTION This invention relates to the medical arts, particularly to the field of transgenics and gene 10 therapy. The invention is particularly directed to in vitro and in vivo methods for genetically modifying male germ cells and support cells (i.e., Leydig and Sertoli cells), which methods incorporate a method of incorporating exogenous genetic material into the genome of a vertebrate to produce transgenic vertebrates and transgenic vertebrate animal lines. 2. DISCUSSION OF THE RELATED ART 15 The field of transgenics was initially developed to understand the action of a single gene in the context of the whole animal and the phenomena of gene activation, expression, and interaction. This technology has been used to produce models for various diseases in humans and other animals. Transgenic technology is amongst the most powerful tools available for the study of genetics, and the understanding of genetic mechanisms and function. 20 It is also used to study the relationship between genes and diseases. About 5,000 diseases are caused by a single genetic defect. More commonly, other diseases are the result of complex interactions between one or more genes and environmental agents, such as viruses or carcinogens. The understanding of such interactions is of prime importance for the development of therapies, such as gene therapy and drug therapies, and also treatments such as organ transplantation. Such treatments 25 compensate for functional deficiencies and/or may eliminate undesirable functions expressed in an organism. Transgenesis has also been used for the improvement of livestock, and for the large scale production of biologically active pharmaceuticals. Historically, transgenic animals have been produced almost exclusively by microinjection of the fertilized egg. The pronuclei of fertilized eggs 30 are microinjected in vitro with foreign, i.e., xenogeneic or allogeneic DNA or hybrid DNA molecules. The microinjected fertilized eggs are then transferred to the genital tract of a pseudopregnant female. (E.g., P.J.A. Krimpenfort et al., Transgenic mice depleted in mature T-cells and methods for making transgenic mice, U.S. Pat. Nos. 5,175,384 and 5,434,340; P.J.A. Krimpenfort et al., Transgenic mice depleted in mature lymphocytic cell-type, U.S. Pat. No. 5,591,669).
WO 00/69257 PCT/USOO/13000 2 This widely used technique requires large numbers of fertilized eggs, equipment to handle embryos and the facility to microinject them in vitro. This is partly because there is a high rate of egg loss due to lysis during microinjection. Moreover manipulated embryos are less likely to implant and survive in utero. These factors contribute to the technique's extremely low efficiency. Superovulated 5 mammals (e.g., primates, cows, horses, pigs, and mice) produce only 10-20 or less eggs per female animal per cycle, even after hormonal stimulation, and only 1% of microinjected mouse eggs (Palmiter, R.D. and Brinster, R.L., Germline transformation of mice, Annu. Rev. Genet. 20:465-99 [1986]), and 0.1% of cattle, sheep and pig eggs (Wall, R.J., et al., Making transgenic livestock: genetic engineering on a large scale, J. Cell Biochem. 49:113-120 [1992]) develop into transgenic 10 animals. Typically, 300-500 fertilized eggs must be microinjected to produce perhaps three transgenic animals. Consequently, generating large animals with these techniques is prohibitively expensive. For this reason, mammalian transgenic technology has been confined almost exclusively to mice due to their high fecundity. Little has been done to improve the generation of transgenic animals by the microinjection of a transgene into fertilized eggs (Gordon, J. and Ruddle, F.H., Integration and stable 15 germ line transmission of genes injected into mouse pronuclei, Science 214:1244-1246 [1981]). While small animals such as mice have proved to be suitable models for certain diseases, their value in this respect is limited. Larger transgenic animals would be much more suitable than mice for the study of the effects and treatment of most human diseases because of their greater similarity to humans in many aspects, and better for studying organ systems or behavior. Larger mammals are also 20 more suitable than mice as potential organ donors to humans due to the comparable size of their organs. Now that transgenic animals with the potential for human xenotransplantation are being developed, more of these larger animals will be required. Transgenic technology will allow that such donor animals will be immunocompatible with the human recipient. In contrast to only 10-20 eggs per female even after treatment with superovulatory drugs, most 25 male mammals, including mice and nearly all larger mammals, generally produce at least about 108 spermatozoa (male germ cells) in each ejaculate. For this reason alone, male germ cells will be a better target for introducing foreign DNA into the germ line, leading to the generation of transgenic animals with increased efficiency and after simple, natural mating. Nevertheless, attempts to generate transgenic mice using spermatozoa to carry DNA into the egg (Lavitrano, M., et al., Sperm cells as 30 vectorsfor introduction of DNA into eggs: genetic transformation of mice, Cell 57: 717-723 [1989]; WO-A-90/08192), have not been validated (Brinster, R. L., et al., No simple solution for making transgenics, Cell 59:239-241 [1989]). Recently, transgenic mice were produced after the injection of exogenous DNA together with sperm heads into oocytes ( Perry, A.C., et al., Mammalian transgenesis by intracytoplasmic sperm injection, Science 284:1180- 1183 [1999]). Following uterine 35 transfer, 20% of these embryos developed into transgenic offspring. Genetic information has been transferred to embryos using retroviral vectors (Jaenisch, R., WO 00/69257 PCT/USOO/13000 3 Germ line integration and Mendelian transmission of the exogenous Moloney leukemia virus, Proc. Natl. Acad. Sci. USA 73:1260-1264 [1976]), but the animals were mosaics with different gene insertions in different tissues. (Jaenisch, R., Retroviruses and embryogenesis: microinjection of Moloney leukemia virus into midgestation mouse embryos, Cell 19:181-188 [1980]). Recently, five 5 transgenic calves were produced by injection of a pseudotyped replication-deficient vector based on the Moloney murine leukemia virus. The vector was introduced into the perivitelline space of metaphase II oocytes (Chan, A.W., et al., Transgenic cattle produced by reverse-transcribed gene transfer in oocytes, Proc. Natl. Acad. Sci. USA 95:14028-14033 [1998]). An alternative, not yet fully realized, is the stable transfection of male germ cells in vitro and 10 their transfer to a recipient testis. Transfer of genetically marked germ cells to the testis yielded offspring, but so far no transgenic progeny have been produced (Brinster, R.L. and Avarbok, M.R., Germline transmission of donor haplotype following spermatogonial transplantation, Proc. Natl. Acad. Sci. USA 91:11303-11307 [1994]). Spermatogenesis is the process by which a diploid spermatogonial stem cell 15 provides daughter cells which undergo dramatic and distinct morphological changes to become self propelling haploid cells (male gametes) capable, when fully mature, of fertilizing an ovum. Primordial germ cells are first seen in the endodermal yolk sac epithelium at E8 and are thought to arise from the embryonic ectoderm (A. McLaren and M. Buehr, Cell Diff. Dev. 31:185 [1992]; Y. Matsui etal., Nature 353:750 [1991]). They migrate from the yolk sac epithelium through 20 the hindgut endoderm to the genital ridges and proliferate through mitotic division to populate the testis. At sexual maturity the spermatogonium goes through 5 or 6 mitotic divisions before it enters meiosis. The primitive spermatogonial stem cells (AO/As) proliferate and form a population of intermediate spermatogonia types Apr, Aal, A1-4 after which they differentiate into type B 25 spermatogonia. The type B spermatogonia differentiate to form primary spermatocytes which enter a prolonged meiotic prophase during which homologous chromosomes pair and recombine. The states of meiosis that are morphologically distinguishable are; preleptotene, leptotene, zygotene, and pachytene; secondary spermatocytes and the haploid spermatids are later stages. Spermatids undergo great morphological changes during spermatogenesis, such as reshaping the nucleus, formation of the 30 acrosome and assembly of the tail (A.R. Bellve et al., Recovery, capacitation, acrosome reaction, and fractionation of sperm, Methods Enzymol. 225:113-36 [1993]). The spermatocytes and spermatids establish vital contacts with the Sertoli cells through unique hemi-junctional attachments with the Sertoli cell membrane. The final changes in the maturing spermatozoan (i.e., spermatozoon) take place in the genital tract of the female prior to fertilization. 35 Initially, attempts were made to produce transgenic animals by adding DNA to spermatozoa which were then used to fertilize mouse eggs in vitro. The fertilized eggs were then transferred to WO 00/69257 PCT/USOO/13000 4 pseudopregnant foster females, and of the pups born, 30% were reported to be transgenic and express the transgene. Despite repeated efforts by others, however, this experiment could not be reproduced and no transgenic pups were obtained. Indeed, there remains little doubt that the transgenic animals reputed to have been obtained by this method were not transgenic at all and the DNA incorporation 5 reported was mere experimental artifact. Data collected from laboratories around the world engaged in testing this method showed that no transgenics were obtained from a total of 890 pups generated. In summary, it is currently possible to produce live transgenic progeny but the available methods are costly and extremely inefficient. Spermatogenic transfection in accordance with this invention, either in vitro or in vivo, provides a simple, less costly and less invasive method of 10 producing transgenic animals and one that is potentially highly effective in transferring allogeneic as well as xenogeneic genes into the animal's germ cells. To facilitate in vitro transfection of male germ cells and implantation into a testis of a recipient male vertebrate it is advantageous first to depopulate the testis of the recipient vertebrate of untransfected male germ cells before transferring transfected male germ cells into it. 15 Depopulation of testis has commonly been done by exposing the whole vertebrate to gamma irradiation (X-ray), or localizing irradiation to the testis. (E.g., G. Pinon-Lataillade et al., Endocrinological and histological changes induced by continuous low dose gamma-irradiation of rat testis, Acta Endocrinol. (Copenh) 109(4):558-62 [1985]; G. Pinon-Lataillade and J. Maas, Continuous gamma-irradiation of rats: dose-rate effect on loss and recovery of spermatogenesis, Strahlentherapie 20 161(7):421-26 [1985]; C.R. Hopkinson et al., The effect of local testicular irradiation on testicular histology andplasma hormone levels in the male rat, Acta Endocrinol. (Copenh) 87(2):413-23 [1978]; G. Pinon-Lataillade et al., Influence of germ cells upon Sertoli cells during continuous low-dose rate gamma-irradiation of adult rats, Mol. Cell Endocrinol. 58(1):51-63 [1988]; P. Kamtchouing et al., Effect of continuous low-dose rate gamma-irradiation on rat Sertoli cellfunction, Reprod. Nutr. Dev. 25 28(4B): 1009-17 [1988]; C. Pineau et al., Assessment of testicularfunction after acute and chronic irradiation: further evidence for influence of late spermatids on Sertoli cellfunction in the adult rat, Endocrinol. 124(6):2720-28 [1989]; M. Kangasniemi et al., Cellular regulation of basal and FSH stimulated cyclic AMP production in irradiated rat testes, Anat. Rec. 227(1):32-36 [1990]; G. Pinon Lataillade et al., Effect of an acute exposure of rat testes to gamma rays on germ cells and on Sertoli 30 and Leydig cellfunctions, Reprod. Nutr. Dev. 31(6):617-29 [1991]). The mechanism of gamma radiation-induced spermatogonial degeneration is thought to be related to the process of apoptosis. (M. Hasegawa et al., Resistance of differentiating spermatogonia to radiation-induced apoptosis and loss in p53-deficient mice, Radiat. Res. 149:263-70 [1998]). Another method of depopulating a vertebrate testis is by administering a composition 35 containing an alkylating agent, such as busulfan (Myleran). (E.g., F.X. Jiang, Behaviour of spermatogonia following recovery from busulfan treatment in the rat, Anat. Embryol. 198(1):53-61 WO 00/69257 PCT/USOO/13000 5 [1998]; L.D. Russell and R.L. Brinster, Ultrastructural observations of spermatogenesis following transplantation of rat testis cells into mouse seminiferous tubules, J. Androl. 17(6):615-27 [1996]; N. Boujrad et al., Evolution of somatic and germ cell populations after busulfan treatment in utero or neonatal cryptochidism in the rat, Andrologia 27(4):223-28 [1995]; R.E. Linder et al., Endpoint of 5 spermatotoxicity in the rat after short duration exposures tofourteen reproductive toxicants, Reprod. Toxicol. 6(6):491-505 [1992]; F. Kasuga and M. Takahashi, The endocrinefunction of rat gonads with reduced number of germ cellsfollowing busulfan treatment, Endocrinol. Jpn 33(1):105-15 [1986]). Cytotoxic alkylating agents, such as busulfan, chlorambucil, cyclophosphamide, melphalan, or ethyl ethanesulfonic acid, are frequently used to kill malignant cells in cancer chemotherapy. (E.g., 10 Andersson et al., Parenteral busulfanfor treatment of malignant disease, U.S. Patent Nos. 5,559,148 and 5,430,057; Stratford et al., Stimulation of stem cell growth by the bryostatins, U.S. Patent No. 5,358,711; Luck et al., Treatment employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion, U.S. Patent No. 4,978,332). Treatment of mice with busulfan (13 mg-40 mg/kg body wt.). was reported to deplete male germs cells in the testis; both stems 15 cells and differentiating spermatogonia were killed; doses over 30mg/kg body weight resulted in azoospermia for up to 56 days after treatment. (L.R. Bucci and M.L. Meistrich, Effects of busulfan on murine spermatogenesis: cytotoxicity, sterility, sperm abnormalities and dominant lethal mutations, Radiation Research 176:259-68 [1987]). The present invention addresses the need for spermatogenic genetic modification, either in 20 vitro or in vivo, that is highly effective in transferring allogeneic as well as xenogeneic genes into the animal's germ cells and in producing transgenic vertebrate animals. The present technology addresses the requirements of germ line and stem cell line gene therapies in humans and other vertebrate species, including the need for a superior method of depopulating a testis of untransfected male germ cells. The present technology is of great value in producing transgenic animals in large species as well as 25 for repairing genetic defects that lead to male infertility. Male germ cells that have stably integrated the DNA are selectable. These and other benefits and features of the present invention are described herein.
WO 00/69257 PCT/USOO/13000 6 SUMMARY OF THE INVENTION The present invention arose from a desire by the present inventors to improve on existing methods for the genetic modification of an animal's germ cells and for producing transgenic animals. The pre-existing art methods rely on direct injection of DNA into zygotes produced in vitro or in vivo, or by the production of chimeric embryos using embryonal stem cells incorporated into a recipient blastocyst. Following this, such treated embryos are transferred to the primed uterus or oviduct. These prior methods are extremely slow and costly, rely on several invasive steps, and only produce transgenic progeny sporadically and unpredictably. In their search for a less costly, faster, and more efficient approach for producing transgenics, the present inventors devised the present method which relies on the in vivo or in vitro (ex vivo) genetic modification of vertebrate male germ cells with a nucleic acid segment, i.e., a polynucleotide, encoding a desired trait or product. The present invention relates to the in vivo and in vitro (ex vivo) genetic modification, for example, by transfection or transduction, of vertebrate animal germ cells with a desired genetic material. Briefly, the in vivo method involves injection of genetic material together with a suitable vector directly into the testicle of the animal. In this method, all or some of the male germ cells within the testicle are genetically modified in situ, under effective conditions. The in vitro method involves obtaining germ cells from the gonad (i.e., testis) of a suitable donor or from the animal's own testis, using a novel isolation or selection method, transfecting or otherwise genetically altering them in vitro, and then returning them to the substantially depopulated testis of the donor or of a different recipient male vertebrate under suitable conditions where they will spontaneously repopulate the depopulated testis. The in vitro method has the advantage that the transfected germ cells can be screened by various means before being returned to the testis of the same or a different suitable recipient male to ensure that the transgene is incorporated into the genome in a stable state. Moreover, after screening and cell sorting only enriched populations of germ cells can be returned. This approach provides a greater chance of transgenic progeny after mating. In particular, the inventive in vivo method of incorporating exogenous genetic material into the genome of a vertebrate involves administering to a male vertebrate's testis(es) a gene delivery mixture comprising a viral vector, such as, but not limited to, a retroviral vector, that comprises at least one polynucleotide defining a gene encoding a desired trait or product and, optionally, a gene encoding a genetic selection marker. The gene(s) are operatively linked to a promoter sequence (all the individual genes used are not necessarily linked to a single promoter sequence), such that a transcriptional unit is formed, and are administered under conditions effective to reach at least one of the spermatozoa, or precursors of spermatozoa, residing in the vertebrate's testis. The delivery mixture, including the polynucleotide(s), are administered in amounts and under conditions effective such that a polynucleotide encoding a desired trait or product is incorporated into the genome of at WO 00/69257 PCTIUSOO/13000 7 least one male germ cell, such as a spermatozoan or precursor cell, so that a genetically modified male gamete is produced by the male vertebrate. Then, the male vertebrate is bred, naturally or with the aid of artificial reproductive technologies, with a female vertebrate of its species such that a transgenic progeny is thereby produced that carries the polynucleotide in its genome. 5 The invention also includes an in vitro method of incorporating at least one polynucleotide encoding a desired trait or product into the genome of a vertebrate. The in vitro method involves obtaining from a donor male vertebrate a male germ cell, such as a spermatozoan cell or a precursor cell, and genetically modifying the cell in vitro with at least one polynucleotide encoding a desired trait or product other than an immortalizing molecule, and a polynucleotide defining a gene encoding 10 a genetic selection marker, in the presence of a gene delivery mixture comprising a viral vector, at about or below the vertebrate's body temperature and for an effective period of time such that the polynucleotide encoding a desired trait or product is incorporated into the genome of the cell. Then the genetically modified germ cell is isolated or selected, with the aid of the genetic selection marker expressed in the genetically modified cell, and transferred to a testis of a recipient male vertebrate such 15 that the cell lodges in a seminiferous tubule of the testis, such that a genetically modified male gamete is produced therein. The male vertebrate is bred with a female vertebrate of its species such that a transgenic progeny is thereby produced that carries the polynucleotide in its genome. This invention also relates to a non-human transgenic male vertebrate produced in accordance with either the in vivo or in vitro method of incorporating exogenous genetic material into the genome 20 of a vertebrate. Produced in accordance with the in vivo method, the transgenic vertebrate is the recipient of the gene delivery mixture. Produced in accordance with the in vitro method, the transgenic vertebrate is the recipient of the genetically modified male germ cell that was transferred to its testis. The transgenic male vertebrate can be bred with a female of its species, because it comprises a native male germ cell carrying in its genome a polynucleotide of exogenous origin 25 defining a gene encoding a desired trait or product. But somatic cells in tissues outside the testis of the transgenic vertebrate lack the polynucleotide. This invention also relates to a non-human transgenic vertebrate produced in accordance with either the in vivo or in vitro method of incorporating exogenous genetic material into the genome of a vertebrate. The non-human transgenic vertebrate is the direct or indirect progeny of the male 30 vertebrate that received the gene delivery mixture, in accordance with the in vivo method. Alternatively, the non-human transgenic vertebrate is the direct or indirect progeny of the recipient of the genetically modified male germ cell that was transferred to its testis, in accordance with the in vitro method. Thus, the transgenic progeny is the immediate offspring of the transgenic male vertebrate, or is an offspring thereof separated by one or more generations. The transgenic vertebrate includes 35 one or more cells carrying in their genome a polynucleotide of exogenous origin that encodes a desired trait or product.
WO 00/69257 PCT/USOO/13000 8 Also, the invention includes a transgenic cell derived from the transgenic progeny. The cell is a germ cell, such as a spermatozoan (i.e., spermatozoon) or ovum, a precursor cell of either of these, or a somatic cell. The invention also relates to vertebrate semen containing a plurality of the inventive transgenic 5 male germ cell. The invention is also directed to a method of producing a non-human transgenic vertebrate animal line comprising native germ cells carrying in their genome at least one xenogeneic polynucleotide. The method involves breeding of the transgenic progeny with a member of the opposite sex of the same species; and selecting its progeny for the presence of the polynucleotide. 10 This technology is applicable to the production of transgenic animals for use as animal models, and to the modification of the genome of an animal, including a human, by addition, modification, or subtraction of genetic material, often resulting in phenotypic changes. The present methods are also applicable to altering the carrier status of an animal, including a human, where that individual is carrying a gene for a recessive or dominant gene disorder, or where the individual is 15 prone to pass a multigenic disorder to his offspring. These and other advantages and features of the present invention will be described more fully in a detailed description of the preferred embodiments which follows. In further describing the invention, the disclosures of related applications U.S. Serial Nos. 09/191,920; 09/292,723; and 09/311,599 are incorporated by reference. 20 BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 illustrates the process of microinjection of gene delivery mixture into a mammalian (mouse) testis. Figure 1(a) shows a preferred site of microinjection into a vas efferens; in mammals, the vasa efferentia connect to the lumen of all seminiferous tubules. Figure 1(b) shows a vas efferens supported by a pipette tip, 1mm diameter. Figure 1(c) shows a mouse testis perfused with 25 bromophenol blue after being injected in the vas efferens. Figure 1(d) shows air bubbles in the testis, confirming satisfactory delivery of viral particles. Figure 2 shows testicular cells transduced by a pseudotyped lentiviral vector expressing Green Fluorescent Protein (GFP) in Zeiss 410 confocal images (wavelength 488 nm; 19 stacked images) of a cryosection of mouse testis. Figure 2(a) shows a transduced Sertoli cell expressing GFP. Figure 30 2(b) shows transduced spermatogonia; GFP expression is visible in the cytoplasm surrounding large dark nuclei. Figure 3 shows a DNA analysis from three consecutive litters of progeny from one male treated in accordance with the in vivo method of incorporating exogenous genetic material into the genome of a vertebrate. The top panel shows GFP-specific PCR amplification products separated on 35 an agarose gel from embryonic DNA of 22 individual progeny. In this run, there was an absence of WO 00/69257 PCT/USOO/13000 9 amplification from fetus No. 2, but other PCR assays confirmed the presence of the transgenic reporter gene. The bottom panel shows a Southern blot analysis of the same DNA. The Southern blot was probed with a radiolabed GFP DNA fragment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS 5 The present method of incorporating exogenous genetic material into the genome of a vertebrate relies on at least one of the following strategies. A first method, an in vivo method of incorporating exogenous genetic material into the genome of a vertebrate, delivers a polynucleotide using known gene delivery systems to male germ cells in situ in the testis of the male vertebrate (e.g., in vivo transfection or transduction), allows the genetically modified germ cells to differentiate in their 10 own milieu, and then selects for progeny animals exhibiting the nucleic acid's integration into its germ cells (transgenic animals). The thus selected progeny can be mated, or their sperm utilized for insemination or in vitro fertilization to produce further generations of transgenic progeny. Alternatively, the in vitro method of incorporating exogenous genetic material into the genome of a vertebrate involves obtaining male germ cells from the testis of a suitable donor or from the 15 animal's own testis, genetically modifying them in vitro, isolating or selecting genetically modified germ cells, and then transferring them to the testis under suitable conditions where they will spontaneously repopulate it. By either the in vivo or in vitro route, the inventive method is suitable for application to a variety of vertebrate animals, all of which are capable of producing gametes, i.e. sperm or ova. Thus, 20 in accordance with the invention novel genetic modification(s) and/or characteristic(s) can be imparted to vertebrates, including mammals, such as humans, non-human primates, for example simians, marmosets, domestic agricultural animals such as ovines (e.g., sheep), bovines (e.g., cattle), porcines (e.g., pigs), equines (e.g., horses), particularly race horses, marine mammals, feral animals, rodents such as mice and rats, gerbils, hamsters, rabbits, and the like. Other vertebrate animals include fowl 25 such as chickens, turkeys, ducks, ostriches, emus, geese, guinea fowl, doves, quail, rare and ornamental birds, and the like. Of particular interest are endangered species of wild animal, such as rhinoceros, tigers, cheetahs, species of condor, and the like. "Gene delivery (or transfection) mixture", in the context of this patent, means selected genetic material together with an appropriate vector mixed, for example, with an effective amount of lipid 30 transfecting agent, for example, a cationic or polycationic lipid, such as polybrene. (E.g., Clark et al., Polycations and cationic lipids enhance adenovirus transduction and transgene expression in tumor cells, Cancer Gene Ther. 6(5):437-46 [1999]). The efficiency of adenoviral-, retroviral-, or lentiviral mediated transduction is enhanced significantly by including polybrene during the infection. The amount of each component of the mixture is chosen so that the genetic modification, e.g., by 35 transfection or transduction, of a specific species of male germ cell is optimized. Such optimization WO 00/69257 PCT/USOO/13000 10 requires no more than routine experimentation. The ratio of DNA to lipid is broad, preferably about 1:1, although other proportions can also be utilized depending on the type of lipid transfecting agent used. (E.g., Banerjee, R. et al. [1999]; Jaaskelainen, I. et al., A lipid carrier with a membrane active component and a small complex size are required for efficient cellular delivery of anti-sense 5 phosphorothioate oligonucleotides, Eur. J. Pharm. Sci. 10(3):187-193 [2000]; Sakurai, F. et al., Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression, J. Controlled Release 66(2-3):255-69 [2000]). "Genetic material", as used herein, means DNA sequences capable of imparting novel genetic 10 modification(s), or biologically functional characteristic(s), to the recipient animal. The novel genetic modification(s) or characteristic(s) can be encoded by one or more genes or gene segments defined by a polynucleotide, or can be caused by removal or mutation of one or more genes, and can additionally contain regulatory sequences, such as, but not limited to enhancers, promoters, or activator/suppressor binding sites. The transfected genetic material is preferably functional, that is 15 it expresses a desired trait by means of a product or by suppressing the production of another. Examples of other mechanisms by which a gene's function can be expressed are genomic imprinting, i.e. inactivation of one of a pair of genes (alleles) during very early embryonic development, or inactivation of genetic material by mutation or deletion of gene sequences, or by repression of a dominant negative gene product, among others. 20 The desired product is any preselected product other than an immortalizing molecule, such as SV40 large T or polyoma virus large T antigens. An immortalizing molecule can transform cells into "cancer-like" cells. "Immortalization" resulting from the expression of an immortalizing molecule can cause a male germ cell to lose many of its important germ cell characteristics, for instance the ability to undergo meiosis, which is crucial for the production of normally functioning male gametes. 25 (E.g., see, Wolkowicz, M.J., Coonrod, S. M., Reddi, P.P. Millan, J. L., Hofmann, M-C, Herr, J.C., Refinement of the differentiated phenotype of the spermatogenic cell line GC-2spd(ts), Biology of Reproduction 55:923-32 [1996]). Male germ cells genetically modified to express an immortalizing molecule are, therefore, not useful for the production of transgenic vertebrate progeny in accordance with the present invention. 30 In addition, novel genetic modification(s) can be artificially induced mutations or variations, or natural allelic mutations or variations of a gene(s). Mutations or variations can be induced artificially by a number of techniques, all of which are well known in the art, including chemical treatment, gamma irradiation treatment, ultraviolet radiation treatment, ultraviolet radiation, the use of specific chimeric DNA/RNA oligonucleotides (chimeraplasty), and the like. Chemicals useful for 35 the induction of mutations or variations include carcinogens such as ethidium bromide and others known in the art.
WO 00/69257 PCTIUSO0/13000 11 DNA segments of specific sequences can also be constructed to thereby incorporate any desired mutation or variant or to disrupt a gene or to alter genomic DNA. Those skilled in the art will readily appreciate that the genetic material is inheritable and is, therefore, present in almost every cell of future generations of the progeny, including the germ cells. Among novel characteristics are the 5 expression of a previously unexpressed trait, augmentation or reduction of an expressed trait, over expression or under expression of a trait, ectopic expression, that is expression of a trait in tissues where it normally would not be expressed, or the attenuation or elimination of a previously expressed trait. Other novel characteristics include the qualitative change of an expressed trait, for example, to palliate or alleviate, or otherwise prevent expression of an inheritable disorder with a multigenic basis. 10 "Transfecting agent", as utilized herein, means a composition of matter added to the genetic material for enhancing the uptake of exogenous DNA segment(s) into a eukaryotic cell, preferably a mammalian cell, and more preferably a mammalian germ cell. The enhancement is measured relative to the uptake in the absence of the transfecting agent. Examples of transfecting agents include adenovirus-transferrin-polylysine-DNA complexes. These complexes generally augment the uptake 15 of DNA into the cell and reduce its breakdown during its passage through the cytoplasm to the nucleus of the cell. These complexes can be targeted to the male germ cells using specific ligands which are recognized by receptors on the cell surface of the germ cell, such as the c-kit ligand or modifications thereof. Other preferred transfecting agents include lipofectin, lipfectamine, DIMRIE C, Superfect, and 20 Effectin (Qiagen), unifectin, maxifectin, DOTMA, DOGS (Transfectam; dioctadecylamidoglycylspermine), DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), DOTAP (1,2-dioleoyl-3-trimethylammonium propane), DDAB (dimethyl dioctadecylammonium bromide), DHDEAB (N,N-di-n-hexadecyl-N,N-dihydroxyethyl ammonium bromide), HDEAB (N-n-hexadecyl N,N-dihydroxyethylammonium bromide), polybrene, or poly(ethylenimine) (PEI). (E.g., Banerjee, 25 R. et al., Novel series of non-glycerol-based cationic transfection lipids for use in liposomal gene delivery, J. Med. Chem. 42(21):4292-99 [1999]; Godbey, W.T. et al., Improved packing of poly(ethylenimine/DNA complexes increases transfection efficiency, Gene Ther. 6(8): 1380-88 [1999]; Kichler, A et al., Influence of the DNA complexation medium on the transfection efficiency of lipospermine/DNA particles, Gene Ther. 5(6):855-60 [1998]; Birchaa, J.C. et al., Physico-chemical 30 characterisation and transfection efficiency of lipid-based gene delivery complexes, Int. J. Pharm. 183(2):195-207 [1999]). These non-viral agents have the advantage that they facilitate stable integration of xenogeneic DNA sequences into the vertebrate genome, without size restrictions commonly associated with virus-derived transfecting agents. "Virus", as used herein, means any virus, or transfecting fragment thereof, which can facilitate 35 the delivery of the genetic material into male germ cells. Examples of viruses which are suitable for use herein are adenoviruses, adeno-associated viruses, retroviruses such as human immune-deficiency WO 00/69257 PCT/USOO/13000 12 virus, lentiviruses, mumps virus, and transfecting fragments of any of these viruses, and other viral DNA segments that facilitate the uptake of the desired DNA segment by, and release into, the cytoplasm of germ cells and mixtures thereof. A preferred viral vector is Moloney murine leukemia virus and the retrovirus vector derived from Moloney virus called vesicular-stomatitis-virus 5 glycoprotein (VSV-G)-Moloney murine leukemia virus. A most preferred viral vector is a pseudotyped (VSV-G) lentiviral vector derived from the HIV virus (Naldini et al. [1996]). Also, the mumps virus is particularly suited because of its affinity for immature sperm cells including spermatogonia. All of the above viruses may require modification to render them non-pathogenic or less antigenic. Other known vector systems, however, are also useful within the confines of the 10 invention. In the in vivo method of incorporating exogenous genetic material into the genome of a vertebrate, administering to a male vertebrate's testis a gene delivery mixture involves the in vivo introduction of the gene delivery mixture to the germ cells by direct delivery into at least one of the animal's testes, where it is distributed to male germ cells at various stages of development. The in 15 vivo method employs injection of the gene delivery mixture, preferably into the seminiferous tubules, or into the rete testis, and most preferably into the vas efferens or vasa efferentia, using, for example, a micropipette. To ensure a steady infusion of the gene delivery mixture, under pressures which will not damage the delicate tubule system in the testis, the injection is made through the micropipette with the aid of a picopump delivering a precise measured volume under controlled amounts of pressure. 20 The micropipette is made of a suitable material, such as, metal or glass, and is usually made from glass tubing which has been drawn to a fine bore at its working tip, e.g. using a pipette puller. The tip can be angulated in a convenient manner to facilitate its entry into the testicular tubule system. Also, the micropipette can be provided with a beveled working end to allow a better and less damaging penetration of the fine tubules at the injection site. This bevel can be produced by means of a specially 25 manufactured grinding apparatus. The diameter of the tip of the pipette for the in vivo method of injection is typically about 15 to 45 microns, although other sizes can be used as needed, depending on the animal's size. The tip of the pipette can be introduced into the rete testis or the tubule system of the testicle, with the aid of a binocular microscope with coaxial illumination, with care taken not to damage the wall of the tubule opposite the injection point, and keeping trauma to a minimum. On 30 average, a magnification of about 25x to 80x is suitable, and bench mounted micromanipulators are not severally required as the procedure can be carried out by a skilled artisan without additional aids. A small amount of a suitable, non-toxic dye, can be added to the gene delivery mixture (fluid) to confirm delivery and dissemination to the seminiferous tubules of the testis. It can include a dilute solution of a suitable, non-toxic dye, which can be visualized and tracked under the microscope. 35 In this manner, the gene delivery mixture reaches and is brought into intimate contact with the male germ cells. Male germ cells include spermatozoa (i.e., male gametes) and developmental WO 00/69257 PCTIUSOO/13000 13 precursors thereof. In fetal development, primordial germ cells are thought to arise from the embryonic ectoderm, and are first seen in the epithelium of the endodermal yolk sac at the E8 stage. From there they migrate through the hindgut endoderm to the genital ridges. In the sexually mature male vertebrate animal, there are several types of cells that are precursors of spermatozoa, and which 5 can be genetically modified, including the primitive spermatogonial stem cells, known as AO/As, which differentiate into type B spermatogonia. The latter further differentiate to form primary spermatocytes, and enter a prolonged meiotic prophase during which homologous chromosomes pair and recombine. Useful precursor cells at several morphological/developmental stages are also distinguishable: preleptotene spermatocytes, leptotene spermatocytes, zygotene spermatocytes, 10 pachytene spermatocytes, secondary spermatocytes, and the haploid spermatids. The latter undergo further morphological changes during spermatogenesis, including the reshaping of their nucleus, the formation of acrosome, and assembly of the tail. The final changes in the spermatozoan (i.e., male gamete) take place in the genital tract of the female, prior to fertilization. The polynucleotide contained in the gene delivery mixture administered in the in vivo method to the testis will reach germ cells that 15 are at any one of the above described stages, and will be taken up preferentially by those that are at a relatively more receptive stage. In the in vitro (ex vivo) method of incorporating exogenous genetic material into the genome of a vertebrate, the male germ cells are preferably, but not exclusively, diploid spermatogonia, which are exposed to or contacted with the gene delivery mixture. Whether employed in the in vivo 20 method or in vitro method, the gene delivery mixture, once in contact with the male germ cells, facilitates the uptake and transport of exogenous genetic material into the appropriate cell location for integration into the genome and expression. A number of known gene delivery methods can be used for the uptake of nucleic acid sequences into the cell. In either the in vivo or vitro method, the gene delivery mixture typically comprises the polynucleotide encoding the desired trait or product, together 25 with a suitable promoter sequence, and optionally agents which increase the uptake of or comprise the polynucleotide sequence, such as liposomes, retroviral vectors, adenoviral vectors, adenovirus enhanced gene delivery systems, or combinations thereof. A reporter construct, including a genetic selection marker, such as the gene encoding for Green Fluorescent Protein, can further be added to the gene delivery mixture. Targeting molecules, such as c-kit ligand, can be added to the gene delivery 30 mixture to enhance the transfer of genetic material into the male germ cell. An immunosuppressing agent, such as cyclosporin or a corticosteroid can also be added to the gene delivery mixture as known in the art. In the in vitro method of incorporating exogenous genetic material into the genome of a vertebrate, the male germ cells are obtained or collected from the donor male vertebrate, by means 35 known in the art. The thus obtained germ cells are then exposed to the gene delivery mixture, preferably within several hours, or cryopreserved for later use.
WO 00/69257 PCT/USOO/13000 14 In one embodiment of the in vitro method, obtaining the male germ cells from the donor vertebrate can be accomplished by transection of the testes. Transection of the isolated testicular tissue can be accomplished, for example, by isolation of the vertebrate's testes, decapsulation and teasing apart and mincing of the seminiferous tubules. The separated cells can then be incubated in 5 an enzyme mixture comprising enzymes known for gently breaking up the tissue matrix and releasing undamaged cells such as, for example, pancreatic trypsin, collagenase type I, pancreatic DNAse type I, as well as bovine serum albumin and a modified DMEM medium. The cells can be incubated in the enzyme mixture for a period of about 5 min to about 30 min, more preferably about 15 to about 20 min, at a temperature of about 33 C to about 37'C, more preferably about 36 to 37'C. After washing 10 the cells free of the enzyme mixture, they can be placed in an incubation medium such as DMEM, and the like, and plated on a culture dish for genetic modification by exposure to the gene delivery mixture. This transection method is not suitable when the donor and recipient male vertebrates are intended to be the same animal, in which case induced a less destructive biopsy method or induced ejaculation by means known in the art is preferred. 15 Any of a number of commercially available gene delivery mixtures can be used, to which the polynucleotide encoding a desire trait or product is further admixed. The final gene delivery mixture comprising the polynucleotide can then be admixed with the cells and allowed to interact for a period of about 2 hrs to about 16 hrs, preferably about 3 to 4 hrs, at a temperature of about 33 C to about 37 C, preferably about 36 C to 37 C, and more preferably in a constant and/or controlled atmosphere. 20 After this period, the cells are preferably placed at a lower temperature of about 33'C to about 34'C, preferably about 30-35'C for a period of about 4 hrs to about 20 hrs, preferably about 16 to 18 hrs. Other conditions which do not deviate radically from the ones described can also be utilized as an artisan would know. With respect to either the in vivo or in vitro methods, a most preferred embodiment employs 25 a retroviral vector system, which was developed for gene therapy (Naldini, L., et al., In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector, Science 272: 263-267 [1996]), which is used to transduce male germ cells in vivo or in vitro. This gene delivery system employs retroviral particles generated by a three-plasmid expression system. In this system a packaging construct contains the human cytomegalovirus (hCMV) immediate early promoter, driving 30 the expression of all viral proteins. The construct's design eliminates the cis-acting sequences crucial for viral packaging, reverse transcription and integration of these transcripts. The second plasmid encodes a heterologous envelope protein (env), namely the G glycoprotein of the vesicular stomatitis virus (VSV-G). The third plasmid, the transducing vector (pHR'), contains cis-acting sequences of human immunodeficiency virus (HIV) required for packaging, reverse transcription and integration, 35 as well as unique restriction sites for cloning heterologous complementary DNAs (cDNAs). For example, a genetic selection marker, such as the enhanced green fluorescent protein (EGFP), and/or WO 00/69257 PCT/USOO/13000 15 a gene encoding another preselected or desired trait or product is cloned downstream of the hCMV promoter in the HR'vector, and is operatively linked so as to form a transcriptional unit. A VSV-G pseudotyped retroviral vector system is capable of infecting a wide variety of cells including cells from different species and of integrating into the genome. Some retroviruses, i.e., lentiviruses, such as HIV, 5 have the ability to infect non-dividing cells. They have a limited capacity for heterologous DNA sequences, the size limit for this vector being 7-7.5 kilobases (Verma, I.M. and Somia, N., Gene Therapy -promises, problems and prospects, Nature 389:239-242 [1997]). In vivo experiments with lentiviruses show that expression does not shut off like other retroviral vectors and that in vivo expression in brain, muscle, liver or pancreatic-islet cells, is sustained at least for over six months 10 the longest time tested so far (Verma and Somia [1997]; Anderson, WF., Human Gene Therapy, Nature (Suppl). 392:25-30 [1998]). For the expression of delivered genetic material by transfection, transduction, or other means to obtain expression of a desired trait or product, a promoter sequence is operatively linked to a polynucleotide sequence encoding the desired trait or product. For purposes of the present invention, 15 "operatively linked" means that, within a transcriptional unit, the promoter sequence, is located upstream (i.e., 5' in relation thereto) from the coding sequence and the coding sequence, is 3' to the promoter, or alternatively is in a sequence of genes 3' to the promoter and expression is coordinately regulated thereby. Both the promoter and coding sequences are oriented in a 5' to 3' manner, such that transcription can take place in vitro in the presence of all essential enzymes, transcription factors, co 20 factors, activators, and reactants, under favorable physical conditions, e.g., suitable pH and temperature. This does not mean that, in any particular cell, conditions will favor transcription. For example, transcription from a tissue-specific promoter is generally not favored in heterologous cell types from different tissues. A promoter sequence is chosen that operates in the cell type of interest and/or under the 25 physiologic or developmental conditions of interest. Useful promoter sequences include constitutive promoters, such as, but not limited to, cytomegalovirus (CMV) promoter, or inducible promoters, such as, but not limited to, the human C-reactive protein (CRP) promoter (e.g., Kanzler, S., et al., TGF beta] in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis, Am. J. Physiol. 276(4Pt 1): G 1059-68 [1999]), or the insulin-like growth factor (IGF-I) promoter (e.g., Meton 30 I., et al., Growth hormone induces insulin-like growthfactor-I gene transcription by synergistic action ofSTAT5 and HNF-1alpha, FEBS Lett. 444(2-3):155-59 [1999]). Useful promoters include those that promote transcription in cells of diverse tissues, such as, but not limited to, an insulin receptor (IR) gene promoter (e.g., Tewari, D.S., et al., Characterization of the promoter region and 3' end of the human insulin receptor gene, J. Biol. Chem. 264(27):16238-45 [1989]); growth hormone receptor 35 (GHR) P2 or P3 promoters (e.g., Jiang, H., et al., Isolation and characterization of a novel promoter for the bovine growth hormone receptor gene, J. Biol. Chem. 274(12):7893-900 [1999]); or a leptin WO 00/69257 PCT/USOO/13000 16 promoter (e.g., Chen, X.L., et al., Analysis of a 762-bp proximal leptin promoter to drive and control regulation of transgene expression of growth hormone receptor in mice, Biochem. Biophys. Res. Commun. 262(1):187-92 [1999]). Also useful for various applications are tissue-selective (i.e., tissue-specific) promoters, i.e., 5 promoters from which expression occurs preferentially in cells of a particular kind of tissue, compared to one or more other types of tissue. Tissue-specific promoters are particularly useful in applications directed to gene therapy or to the genetic enhancement of non-human vertebrates. For example, a promoter sequence, which is only active in cycling spermatogonial stem cell populations can be used for differential expression in male germ cells, for example, B-Myb or a male 10 germ cell-specific promoter, such as the c-kit promoter region, c-raf-1 promoter, ATM (ataxia telangiectasia) promoter (also active in cerebellar cells and thymocytes), vasa promoter, cyclin Alpromoter, RBM (ribosome binding motif) promoter, DAZ (deleted in azoospermia) promoter, XRCC-1 promoter, HSP 90 (heat shock gene) promoter, or FRMI (from fragile X site) promoter. For hematopoietic tissue-selective expression in hematopoietic precursor cells, useful 15 promoters include cyclin Al promoters (e.g., MUller, C., et al., Cloning of the cyclin Al genomic structure and characterization of the promoter region, J. Biol. Chem. 276(16):11220-28 [1999]); CD34 promoters (e.g., Burn, T.C., et al., Hematopoietic stem cell specific gene expression, U.S. Patent No. 5,556,954); a c-kit promoter, or an integrin alphallb promoter (e.g., Wilcox, D.A., et al., Integrin alphalib promoter-targeted expression of gene products in megakarvocytes derived from retrovirus 20 transduced human hematopoietic cells, Proc. Natl. Acad. Sci. USA 96(17):9654-59 [1999]). Cartilage-selective promoters for expression in chondrocytes, for example, an osteocalcin (OC) promoter (e.g., Newberry, E.P., et al., The RRM domain of MINT, a novel Msx2 binding protein, recognizes and regulates the rat osteocalcin promoter, Biochemistry 38(33):10678-90 [1999]); a SOX9 promoter, aggrecan gene promoter (AGC1), or collagen oligomeric matrix protein (COMP) 25 gene promoter (e.g., Kanai, Y. & Koopman, P., Structural and functional characterization of the mouse Sox9 promoter: implicationsfor campomelic dysplasia, Hum. Mol. Genet. 8(4):691-96 [1999]; Newton et al., Characterization of human and mouse cartilage oligomeric matrix protein, Genomics 24:435-39 [1994); or a promoter from a collagen gene, such as, but not limited to promoters for COL2A1, COL9A1, or COL10AL. (e.g., Ganguly, A., et al., Targeted insertions of two exogenous 30 collagen genes into both alleles of their endogenous loci in cultured human cells: the insertions are directed by relatively shortfragments containing the promoters and the 5' ends of the genes, Proc Natl Acad Sci USA 91(15):7365-9 [1994]; Dharmavaram, R. M., et al., Detection and characterization of Spi binding activity in human chondrocytes and its alterations during chondrocyte dedifferentiation, J. Biol Chem 272(43):26918-25 [1997]; Zhou, G., et al., Three high mobility group-like sequences 35 within a 48-base pair enhancer of the Col2al gene are required for cartilage-specific expression in vivo, J. Biol Chem 273(24):14989-97 [1998]; Seghatoleslami, M. R., et al., Differential regulation of WO 00/69257 PCT/USOO/13000 17 COL2A1 expression in developing and mature chondrocytes, Matrix Biol 14(9):753-64 [1995]; Lefebvre, V., et al., An 18-base-pair sequence in the mouse proalphal(II) collagen gene is sufficient for expression in cartilage and binds nuclear proteins that are selectively expressed in chondrocytes, Mol Cell Biol 16(8):4512-23 [1996]; Zhou, G., et al., A 182 bpfragment of the mouse pro alpha 1(11) 5 collagen gene is sufficient to direct chondrocyte expression in transgenic mice, J. Cell Sci, 108(Pt 12):3677-84 [3677-84]; Mukhopadhyay, K., et al., Use of a new rat chondrosarcoma cell line to delineate a 119-base pair chondrocyte-specific enhancer element and to define active promoter segments in the mouse pro-alpha 1(II) collagen gene, J. Biol Chem 270(46):27711-9 [1995]; Vikkula, M., et al., Structural analysis of the regulatory elements of the tyupe-II procollagen gene. 10 Conservation of promoter and first intron sequences between human and mouse, Biochem J 285(Pt 1):287-94 [1992]; Beier, F., et al., Localization of silencer and enhancer elements in the human type X collagen gene, J Cell Biochem 662(2):210-8 [1997]; Thomas, J. T., Sequence comparison of three mammalian type-X collagen promoters and preliminary functional analysis of the human promoter, Gene 160(2):291-6 [1995]; Apte, S. S., Characterization of the mouse type X collagen gene, Matrix 15 13(2):165-79 [1993]). A cartilage-derived retinoic acid-sensitive protein (CD-RAP) gene promoter is also useful for cartilage-selective expression by chondrocytes. (e.g., Xie, W.F., et al., Transactivation of the mouse cartilage derived retinoic acid-sensitive protein gene by Sox9, J. Bone Miner. Res. 14(5):757-63 [1999]). For liver-selective expression in hepatocytes, useful promoter sequences include, an albumin 20 gene promoter (e.g., Pastore, L., et al., Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors, Hum. Gen. Ther. 10(11): 1773-81 [1999]); a CYP7A or CYP7A1 promoter (e.g., Nitta, M., et al., CPF: an orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7alpha-hydroxylase gene, Proc. Natl. Acad. Sci. USA 96(12):6660-65 [1999]; Chen, J., et al., Hepatocyte nuclear factor 1 binds to and transactivates the 25 human but not the rat CYP7A1 promoter, Biochem. Biophys. Res. Commun. 260(3):829-34 [1999] ); a GHR P1 promoter (e.g., Zou, L., et al., Isolation of a liver-specific promoterfor human growth hormone receptor gene, Endocrinology 138(4):1771-74 [1997]; Jiang, H., et al. [1999]; Adams, T.E., Differential expression of growth hormone receptor messenger RNA from a second promoter, Mol. Cell Endocrinol. 108(1-2):23-33 [1995]); or a thrombin-activatable fibrinolysis inhibitor (TAFI) 30 promoter (e.g., Boffa, M.B., et al., Characterization of the gene encoding human TAFI [thrombin activatable fibrinolysis inhibitor; plasma procarboxypeptidase B], Biochemistry 38(20):6547-58 [1999]). Neuronal specific promoters are also useful, for example, a neurofilament promoter or a neural-specific enolase promoter.
WO 00/69257 PCT/USOO/13000 18 Many other tissue specific promoters are useful for tissue specific expression of a preselected gene for phenotypic expression of a desired trait or product in the various tissues or organs of the vertebrate body. Other useful promoters are related to the expression of cytokine-inducible proteins, including 5 promoters that regulate the expression of products and modulators of the Jak-STAT signaling cascade, for example, a SOCS-3 promoter (C.J. Auernhammer et al., Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter, Proc. Natl. Acad Sci. USA 96:6964-69 [1999]), a STAT-3 promoter (C. Bousquet & S. Melmed, J. Biol. Chem. 274:10723-30 [1999]), a POMC promoter (C.J. Auernhammer et al. [1998b]), or Spi 2.1 promoter (T.E. Adams et 10 al. [1995]). Useful promoters also include exogenously inducible promoters. These are promoters that can be "turned on" in response to an exogenously supplied agent or stimulus, which is generally not an endogenous metabolite or cytokine. Examples include an antibiotic-inducible promoter, such as a tetracycline-inducible promoter; a heat-inducible promoter; a light-inducible promoter; or a laser 15 inducible promoter. (E.g., Halloran, M.C. et al., Laser-induced gene expression in specific cells of transgenic zebrafish, Development. 127(9):1953-1960 [2000]; Gerner, E.W. et al., Heat-inducible vectorsfor use in gene therapy, Int. J. Hyperthermia 16(2):171-81 [2000]; Rang, A.. and Will, H., The tetracycline-responsive promoter contains functional interferon-inducible response elements, Nucleic Acids Res. 28(5):1120-5 [2000]; Hagihara Y. et al., Long-term functional assessment of 20 encapsulated cells transfected with Tet-On system, Cell Transplant. 8(4):431-4 [1999]; Huang, C.J. et al., Expression of green fluorescent protein in oligodendrocytes in a time- and level-controllable fashion with a tetracycline-regulated system, Mol. Med. 5(2):129-37 [1999]; Forster, K. et al., Tetracycline-inducible expression systems with reduced basal activity in mammalian cells, Nucleic Acids Res. 27(2):708-10 [1999]; Liu, H.S. et al., Lac/Tet dual-inducible system functions in 25 mammalian cell lines, Biotechniques 24(4):624-8, 630-2 [1998]). Other useful promoters include developmentally or temporally regulated promoters. Examples include the myelin PO promoter (P. Thatikunta et al., Reciprocal Id expression and myelin gene regulation in Schwann cells, Mol. Cell Neurosci. 14(6):519-28 [1999]), Gabra3 or GABRA3 promoters (W. Mu and D.R. Burt, the mouse GABA(A) receptor alpha3 subunit gene and promoter, 30 Brain Res. Mol. Brain Res. 73(1-2):172-80 [1999]), tyrosine hydroxylase promoter (J.J. Schimmel et al., 4.5 kb ofthe rat tyrosine hydroxylase 5 'flanking sequence directs tissue specific expression during development and contains consensus sites for multiple transcription factors, Brain Res. Mol. Brain Res. 74(1-2):1-14 [1999]), vimentin promoters (A. Benazzouz and P. Duprey, The vimentin promoter as a tool to analyze the early events of retinoic acid-induced differentiation of cultured embryonal 35 carcinoma cells, Differentiation (65(3):171-80 [1999]), GATA-6 promoters (A. Brewer et al., The human and mouse GATA-6 genes utilize two promoters and two initiation codons, J. Biol. Chem.
WO 00/69257 PCTIUSOO/13000 19 274(53):38004-16 [2000]), SHIP1 or SHIP2 promoters (S. Schurmans et al., The mouse SHIP2 (Inppll)gene: complementary DNA, genomic structure, promoter analysis, and gene expression in the embryo and adult mouse, Genomics 62(2):260-71 [1999]), or hGH-N promoters (B.M. Shewchuk et al., Pit-i binding sites at the somatotrope-specific DNase I hypersensitive sites I, II, of the human 5 growth hormone locus control region are essential for in vivo hGH-N gene activation, J. Biol. Chem. 274(50):35725-33 [1999]). The foregoing examples of useful promoter sequences are by no means an exhaustive list, but are merely illustrative of the promoters available to the skilled artisan in practicing the present invention. 10 The in vivo and in vitro methods of incorporating exogenous genetic material into the genome of a vertebrate involve incorporating the polynucleotide encoding a desired trait or product into the genome of at least one spermatozoan or precursor thereof, so that a genetically modified male gamete is produced by the male vertebrate. Thus, the genetically modified germ cells of the vertebrate animal, now transgenic, have the non-endogenous (exogenous) genetic material integrated into their 15 chromosomes. This is what is often referred to as a "stable transfection" or "stable integration". This is applicable to all vertebrate animals, including humans. Animals that are shown to carry suitably modified sperm cells then can be either allowed to mate naturally, or alternatively their spermatozoa are used for insemination or in vitro fertilization. Isolating and/or selecting of genetically modified cells, including transgenic germ cells and 20 transgenic somatic cells, and of transgenic vertebrates, is by any suitable means, such as, but not limited to, physiological and/or morphological phenotypes of interest using any suitable means, such as biochemical, enzymatic, immunochemical, histologic, electrophysiologic, biometric or like methods; and analysis of cellular nucleic acids, for example the presence or absence of specific DNAs or RNAs of interest using conventional molecular biological techniques, including hybridization analysis, 25 nucleic acid amplification (such as but not limited to, polymerase chain reaction [PCR], reverse transcriptase-mediated polymerase chain reaction [RT-PCR], transcription-mediated amplification [TMA], reverse transcriptase-mediated ligase chain reaction [RT-LCR]), and/or electrophoretic technologies. In a preferred embodiment, the gene delivery mixture includes at least one polynucleotide 30 comprising a gene encoding a genetic selection marker that is operatively linked to a promoter sequence such that a transcriptional unit is formed. The promoter sequence can be the same or different from the promoter regulating the expression from the gene encoding the desired trait or product. The genetic selection marker, also known as a reporter gene, is, for example, a gene encoding an enzyme, such as P-galactosidase, or encoding a fluorescent protein, such as Green 35 Fluorescent Protein (GFP), enhanced Green Fluorescent Protein (EGFP), Yellow Fluorescent Protein, WO 00/69257 PCT/USOO/13000 20 Blue Fluorescent Protein, a phycobiliprotein, such as phycoerythrin or phycocyanin, or any other protein which fluoresces under a suitable wave-length. Another preferred genetic selection marker or reporter gene, suitable for some applications is a gene encoding a protein that can enzymatically lead to the emission of light from a substrate(s); 5 for purposes of the present invention, such a protein is a "light-emitting" or luminescent protein. For example, a light-emitting protein includes proteins such as luciferase or apoaequorin. Transgenic cells expressing a fluorescent or luminescent protein encoded by the reporter construct can be sorted with the aid of, for example, a flow activated cell sorter (FACS) set at the appropriate wavelength(s), or they can be selected by chemical methods. 10 A preferred method of isolating or selecting male germ cell populations, comprises obtaining specific male germ cell populations, such as spermatogonia, from a mixed population of testicular cells by extruding the cells from the seminiferous tubules and gentle enzymatic disaggregation. The spermatogonia or other male germ cell populations, which are to be genetically modified, can be isolated from a mixed cell population by a method including the utilization of a promoter sequence, 15 which is specifically or selectively active in cycling male germ line stem cell populations, for example, B-Myb or a specific promoter, such as the c-kit promoter region, c-raf-1 promoter, ATM (ataxia-telangiectasia) promoter, vasa promoter, RBM (ribosome binding motif) promoter, DAZ (deleted in azoospermia) promoter, XRCC-1 promoter, HSP 90 (heat shock gene) promoter, cyclin Al promoter, or FRMI (from fragile X site) promoter, linked to a reporter construct, for example, a 20 construct comprising a gene encoding Green Fluorescent Protein (or EGFP), Yellow Fluorescent Protein, Blue Fluorescent Protein, a phycobiliprotein, such as phycoerythrin or phycocyanin, or any other protein which fluoresces under suitable wave-lengths of light, or encoding a light-emitting protein, such as luciferase or apoaequorin. These unique promoter sequences drive the expression of the reporter construct only during specific stages of male germ cell development, as is known to those 25 skilled in the art. (E.g., Muller, C., et al., Cloning of the cyclin Al genomic structure and characterization of the promoter region, J. Biol. Chem. 276(16):11220-28 [1999]; Schrans-Stassen, B., H. et al., Differential expression of c-kit in mouse undifferentiated and differentiating type A spermatogonia, Endocrinology 140:5894-5900 [1999]). Populations of male germ cells at specific developmental stages, thus, are the only cells in the mixed population which will express the reporter 30 construct(s) and they, thus, can be isolated on this basis. In the case of a fluorescent reporter construct, the cells can be sorted with the aid of, for example, a FACS set at the appropriate wavelength(s), or they can be selected by chemical methods. Further with respect to the in vitro method of incorporating exogenous genetic material into the genome of a vertebrate, in which male germ cells are obtained from a donor animal and genetically 35 modified in vitro to impart a gene encoding a desired trait or product, male germ cells which exhibit any evidence that the DNA has been modified in the desired manner are isolated or selected, and WO 00/69257 PCTUSOO/13000 21 transferred to the testis of a suitable recipient animal. After transfer, further selection can be attempted after biopsy of one or both of the recipient male's testes, or after examination of the animal's ejaculate amplified by the polymerase chain reaction to confirm whether the desired nucleic acid sequence was actually incorporated. As described above, the initial gene delivery can have included a reporter gene, 5 such as a gene encoding the Green Fluorescent Protein, enhanced Green Fluorescent Protein (EGFP), Yellow Fluorescent Protein, Blue Fluorescent Protein, a phycobiliprotein, such as phycoerythrin or phycocyanin, or any other protein which fluoresces under light of suitable wave-lengths, or encoding a light-emitting protein. In the in vitro method of incorporating exogenous genetic material into the genome of a 10 vertebrate, the genetically modified germ cells, thus isolated or selected, are preferably transferred to a testis of a recipient male vertebrate, which can be, but need not be, the same donor animal. Before transferring the genetically modified male germ cells to one or more of the testes of the recipient male vertebrate, the testes of the recipient animal are preferably depopulated of native germ cells. Substantial depopulation of the endogenous male germ cells facilitates the colonization of the 15 recipient testis by the genetically modified germ cells from the donor animal. The depopulation can be done by any suitable means, including by gamma irradiation, by chemical treatment, by means of infectious agents such as viruses, or by autoimmune depletion or by combinations thereof. Whichever means of depopulating the testis of endogenous male germ cells is used, the basic rigid architecture of the gonad should not be destroyed, nor badly damaged. If there is disruption of 20 the fine system of tubule formation, it may be impossible for the exogenous spermatogonia to repopulate the testis. Disruption of tubules would also presumably lead to impaired transport of testicular sperm and result in infertility. Any controlled testicular injury of this kind should also be limited so that the Sertoli cells are not irreversibly damaged, as they are needed to provide a base for development of the germ cells during maturation. Moreover they may play a role in preventing the 25 host immune defense system from destroying grafted foreign spermatogonia. But vertebrate testes are most preferably depopulated by a combined treatment of the vertebrate with an alkylating agent and gamma irradiation in accordance with the inventive method of substantially depopulating a vertebrate testes. The method involves a treatment with a cytotoxic alkylating agent, such as, but not limited to, busulfan (1,4-butanediol dimethanesulphonate; Myleran, 30 Glaxo Wellcome), chlorambucil, cyclophosphamide, melphalan, or ethyl ethanesulfonic acid, combined with gamma irradiation, to be administered in either sequence. The combination of a dose of an alkylating agent and a dose of gamma radiation yields unexpectedly superior results in depopulating the testes of germ cells, compared to either treatment alone. The dose of the alkylating agent and the dose of gamma radiation are in an amount sufficient to substantially depopulate the 35 testis.
WO 00/69257 PCTIUSOO/13000 22 The preferred dose of alkylating agent is about 4 to 10 milligrams per kilogram of body weight, and about 6 to 8 milligrams per kilogram of body weight is most preferred. The alkylating agent can be administered by any pharmaceutically acceptable delivery system, including but not limited to, intraperitoneal, intravenous, or intramuscular injection, intravenous drip, implant, transdermal or 5 transmucosal delivery systems. A recovery period between the administration of alkylating agent and irradiation is not essential, and the two treatments are most preferably done within zero to 24 hours of each other. Preferably, the time between the two treatments should not exceed 2 weeks, because this yields less than optimal results for purposes of transferring genetically modified or heterologous male germ cells 10 to recipient testes. The recipient vertebrate is gamma irradiated with a dose of about 200 to 800 Rads, most preferably about 350 to 450 Rads, directed locally to the testis to be depopulated. Less than 200 Rad yields little effect; greater than 800 Rad commonly produces symptoms of radiation sickness, particularly in the gastrointestinal tract. Within 3 days to 2 months after treatment to depopulate the 15 recipient testis(es) in accordance with the present method, male germ cells can be transferred thereto as described herein. Prior to three days, traces of cytotoxic alkylating agent or endogenous apoptotic signal molecules may remain in the recipient testis to harm the male germ cells transferred thereto. After two months, the endogenous population of male germ cells will typically begin to restablish itself, yielding less than optimal results when transfected, genetically altered, or heterologous male 20 germ cells are transferred to a recipient testes for breeding purposes. Thus in the in vitro (ex vivo) method, preferably within three days to two months after the final treatment to depopulate the testis(es) of the recipient male vertebrate, the gene delivery mixture is administered to the male germ cells of the donor vertebrate, in vitro, in sufficient amount and under effective conditions such that one or more of them is genetically modified. Genetically modified male 25 germ cells from the donor male vertebrate can then be transferred to the testis(es) of the recipient male such that they lodge in a seminiferous tubule of the testis, where they then mature into genetically modified gametes. Transferring the isolated or selected genetically modified germ cells into the recipient testis can be accomplished by direct injection using a suitable micropipette. Support cells, such as Leydig 30 or Sertoli cells that provide hormonal stimulus to spermatogonial differentiation, can be transferred to a recipient testis along with the modified germ cells. These transferred support cells can be unmodified, or, alternatively, can themselves have been genetically modified, together with- or separately from the germ cells. These transferred support cells can be autologous or heterologous to either the donor or recipient testis. A preferred concentration of cells in the transfer fluid can easily 35 be established by simple experimentation, but will likely be within the range of about 1 x 10' - 10 x 105 cells per 10 pl of fluid. This micropipette can be introduced into the vasa efferentia, the rete testis WO 00/69257 PCT/USOO/13000 23 or the seminiferous tubules, optionally with the aid of a picopump to control pressure and/or volume, or this delivery can be done manually. The micropipette employed is in most respects similar to that used for the in vivo injection, except that its tip diameter generally will be about 45 to about 70 microns. The microsurgical method of introduction is similar in all respects to that used for the in vivo 5 method described above. A suitable dyestuff or bubbles (less than 1 mm in diameter) can also be incorporated into the carrier fluid for easy identification of satisfactory delivery of the transfected germ cells to at least one seminiferous tubule of the testis (Figure 1). With respect to both the in vivo and in vitro methods of incorporating exogenous genetic material into the genome of a vertebrate involves, breeding the male vertebrate with a female 10 vertebrate of its species means causing the union of male and female gametes so that fertilization occurs and a transgenic zygote is formed; a transgenic progeny or offspring is thereafter produced during gestation of the developing fetus. A union of male and female gametes is brought about by natural mating, i.e., copulation by the male and female vertebrates of the same species, or by in vitro or in vivo artificial means. If artificial means are chosen, then incorporating into the genome a genetic 15 selection marker that is expressed in male germ cells is particularly useful. Preferably expression of the genetic selection marker is regulated from a constitutive or male germ-cell specific promoter, operatively linked to the gene encoding the genetic selection marker. Artificial means include, but are not limited to, artificial insemination, in vitro fertilization (IVF) and/or other artificial reproductive technologies, such as intracytoplasmic sperm injection 20 (ICSI), subzonal insemination (SUZI), or partial zona dissection (PZD). However, others, such as cloning and embryo transfer, cloning and embryo splitting, and the like, can also be employed. The thus obtained transgenic vertebrate progeny can, in turn, also be bred, whether by natural mating, artificial insemination, or by in vitro fertilization (IVF) and/or other artificial reproductive technologies, such as intracytoplasmic sperm injection (ICSI), subzonal insemination (SUZI), or partial 25 zona dissection (PZD), to obtain further generations of transgenic progeny. Those skilled in the art will readily appreciate that any desired traits generated as a result of changes to the genetic material of any transgenic animal produced by the inventive method are inheritable. Although the genetic material was originally inserted solely into the germ cells of a parent animal, it will ultimately be present in the germ cells of future progeny and subsequent generations thereof. In addition, the 30 genetic material is also present in cells of the progeny other than germ cells, i.e., somatic cells. Broadly speaking, a "transgenic" vertebrate is one that has had foreign or exogenous DNA permanently introduced into its cells. The exogenous genes which have been introduced into the animal's cells are called "transgenes" and are xenogeneic and/or allogeneic transgenic genetic material, including biologically functional genetic material. The present invention is applicable to the 35 production of transgenic animals containing xenogeneic, i.e., exogenous DNA from a different species, either in its native, undisturbed form, or in artificially mutated form. In other embodiments, the WO 00/69257 PCT/USOO/13000 24 genetic material is "allogeneic" genetic material, exogenous transgenic material obtained from a different strain, race, breed, or individual of the same species, for example, from an animal having a "normal" form of a gene, or a desirable allele, variant, or mutation thereof. Also the gene can be a hybrid construct consisting of promoter DNA sequences and DNA coding sequences operatively 5 linked together. These sequences can be obtained from different species or DNA sequences from the same species that are not normally juxtaposed. The DNA construct can also contain DNA sequences from prokaryotic organisms, such as bacteria, or from viruses. The transfected germ cells of the transgenic vertebrate animal preferably have the non-endogenous (exogenous) genetic material integrated into their chromosomes. Those skilled in the 0 art will readily appreciate that any desired traits generated as a result of changes to the genetic material of any transgenic vertebrate produced by this invention are heritable. Although the genetic material was originally inserted solely into the germ cells of a parent animal, it will ultimately be present in the germ cells of direct progeny and subsequent generations thereof. The genetic material is also present in the differentiated cells, i.e. somatic cells, of the progeny. 15 Included in the invention is a non-human transgenic male vertebrate produced by the in vivo or in vitro method of incorporating exogenous genetic material into the genome of a vertebrate. Produced in accordance with the in vivo method, the transgenic vertebrate is the recipient of the gene delivery mixture. Alternatively, the non-human transgenic male vertebrate is the recipient of the genetically modified male germ cell that was transferred to its testis, in accordance with the in vitro 20 method. The transgenic male vertebrate can be bred with a female of its species, because it comprises a native male germ cell carrying in its genome a polynucleotide of exogenous origin defining a gene encoding a desired trait or product. But somatic cells in tissues outside the testis of the transgenic vertebrate lack the polynucleotide. Preferably, but not necessarily, the transgenic male vertebrate will continue to produce genetically modified gametes for an indefinite period. However, in some 25 embodiments the transgenic state is temporary, lasting for at least several weeks or months, after which non-modified gametes are again exclusively or predominantly produced by the animal. Also included in the invention is a non-human transgenic vertebrate produced in accordance with the in vivo or in vitro method of incorporating exogenous genetic material into the genome of a vertebrate, wherein the non-human vertebrate is the direct or indirect progeny of the transgenic male 30 vertebrate described above. Thus, this transgenic progeny is the immediate offspring, male or female, of the transgenic male vertebrate or is an offspring thereof separated by one or more generations. The transgenic vertebrate includes one or more cells carrying in their genome a polynucleotide of exogenous origin that encodes a desired trait or product. Also, the invention includes a transgenic cell derived from the transgenic vertebrate progeny. 35 The cell is a germ cell, such as a spermatozoan or ovum, a precursor germ cell of either of these, or a somatic cell.
WO 00/69257 PCTIUSOO/13000 25 Male germ cells are obtained from a male animal's semen, or spermatozoa, spermatogonia, or immature spermatocytes are separated from whole biopsies of testicular tissue containing the male germ cells. Alternatively, male germ line stem cells can be isolated from embryonic tissue. Female germ cells are obtained by known means, including hormonally induced "ripening" and harvesting 5 from the oviducts or aspiration by way of the cervix or by way of a laparoscopic incision. Somatic cells include stem cells. A stem cell is an undifferentiated mother cell that is self renewable over the life of the organism and is multipotent, i.e., capable of generating various committed progenitor cells that can develop into fully mature differentiated cell lines. (E.g., T. Zigova and P.R. Sanberg, The rising star of neural stem cell research, Nature Biotechnol. 16(11):1007-08 10 [ 1998]). All vertebrate tissues arise from stem cells, including hematopoietic stem cells, from which various types of blood cells derive; ectodermal stem cells; neural stem cells, for example, neural progenitors from which brain and nerve tissues derive. Somatic cells also include progenitor cells or terminally differentiated cells of any kind associated with any tissue or organ of the vertebrate body. Somatic cells are obtained by known sampling or biopsy means from any bodily tissue, organ, 15 or fluid, including but not limited to, blood, heart, kidney, ureter, bladder, urethra, brain, thyroid, parotid gland, pancreas, hypothalamus, pituitary gland, submaxillary gland, sublingual gland, lymph node, bone, bone marrow, cartilage, lung, mediastinum, breast, uterus, ovary, testis, prostate, cervix uteri, endometrium, liver, spleen, adrenal, esophagus, stomach, intestine, hair root, muscle, nerve, urine, amniotic fluid, chorionic villus, skin, vascular or oral epithelium, or spinal fluid. The inventive 20 transgenic cells can be cultured or stored by well known means. The invention also relates to vertebrate semen containing a plurality of the inventive transgenic male germ cell. The inventive vertebrate semen is useful for breeding or other suitable purposes. The semen is obtained from ejaculate produced by the inventive transgenic male vertebrate or its transgenic male progeny (either immediate progeny or progeny separated by one or more generations), and 25 methods of inducing ejaculation by a male vertebrate and capturing the semen are well known. The semen can be processed, e.g., by washing, and/or stored by means such as are known in the art. For example, storage conditions include the use of cryopreservation using programmed freezing methods and/or the use of cryoprotectants, for example, dimethyl sulfoxide (DMSO), glycerol, trehalose, or propanediol-sucrose, and the use of storage in substances such as liquid nitrogen. 30 Such storage techniques are particularly beneficial to young adult humans or children, undergoing oncological treatments for such diseases such as leukemia or Hodgkin's lymphoma. These treatments frequently irreversibly damage the testicle and, thus, render it unable to recommence spermatogenesis after therapy by, for example, irradiation or chemotherapy. In species other than humans, the present techniques are valuable for transport of gametes as frozen germ cells. Such 35 transport will facilitate the establishment of various valued livestock or fowl lines, at a remote distance WO 00/69257 PCT/USOO/13000 26 from the donor animal. This approach is also applicable to the preservation of endangered species across the globe. Thus, the invention is also includes a method of producing a non-human transgenic vertebrate animal line, the individuals of which comprise native germ cells carrying in their genome at least one 5 xenogeneic polynucleotide. The transgenic vertebrates bred with other transgenic or non-transgenic animals of the same species will produce some transgenic progeny, including fertile individuals. The method involves breeding of the fertile transgenic progeny with a member of the opposite sex of the same species as described above; and selecting its progeny for the presence of the polynucleotide. The inventive method of producing a non-human transgenic vertebrate animal line is simple and 10 efficient, and is more easily accomplished in large mammals than in mice because of the larger size of the testicular ducts. Far fewer animals are needed to produce transgenic progeny by genetic modification of male germ cells, which can be produced continually from repeated mating without interruption by pregnancy or parturition. It requires no expensive equipment, nor the training necessary for microinjection. 15 The inventive technology is applicable to the field of gene therapy, since it permits the introduction of genetic material encoding and regulating specific genetic traits. Thus, in the human, for example, by treating parents it is possible to correct many single gene disorders which otherwise might affect their children. It is similarly possible to alter the expression of fully inheritable disorders or those disorders having at least a partially inherited basis, which are caused by interaction of more 20 than one gene, or those which are more prevalent because of the contribution of multiple genes. This technology can also be applied in a similar way to correct disorders in animals other than human primates. In some instances, it may be necessary to introduce one or more "gene(s)" into the germ cells of the animal to attain a desired therapeutic effect, as in the case where multiple genes are involved in the expression or suppression of a defined trait. In the human, examples of multigenic 25 disorders include diabetes mellitus caused by deficient production of, or response to, insulin, inflammatory bowel disease, certain forms of atheromatous cardiovascular disease and hypertension, schizophrenia and some forms of chronic depressive disorders, among others. In some cases, one gene can encode an expressible product, whereas another gene encodes a regulatory function, as is known in the art. Other examples are those where homologous recombinant methods are applied to repair 30 point mutations or deletions in the genome, inactivation of a gene causing pathogenesis or disease, or insertion of a gene that is expressed in a dominant negative manner, or alterations of regulating elements such as gene promoters, enhancers, the untranslated tail region of a gene, or regulation of expansion of repeated sequences of DNA which cause such diseases as Huntingdon's chorea, Fragile-X syndrome and the like. 35 A specific reproductive application of the present invention is to the treatment of animals, particularly humans, with disorders of spermatogenesis. Defective spermatogenesis or spermiogenesis WO 00/69257 PCT/USOO/13000 27 frequently has a genetic basis, that is, one or mutations in the genome can result in failure of production of normal sperm cells. This can happen at various stages of the development of germ cells, and may result in male infertility or sterility. The present invention is applicable, for example, to the insertion or incorporation of nucleic acid sequences into a recipient's genome and, thereby, establish 5 spermatogenesis in the correction of oligozoospermia or azoospermia in the treatment of infertility. Similarly, the present methods are also applicable to males whose subfertility or sterility is due to a motility disorder with a genetic basis. The present invention is additionally applicable to the generation of transgenic animals expressing agents which are of therapeutic benefit for use in human and veterinary medicine or well 10 being. Examples include the production of pharmaceuticals in domestic cows' milk, such as factors which enhance blood clotting for patients with types of haemophilia, or hormonal agents such as insulin and other peptide hormones. The present method is further applicable to the generation of transgenic animals, for example pigs, of a suitable anatomical and physiological phenotype for human xenograft transplantation. The 15 inventive transgenic technology permits the generation of animals which are immune-compatible with a human recipient. Appropriate organs, for example, can be removed from such animals to allow the transplantation of, for example, the heart, lung and kidney. In addition, male germ cells genetically modified in accordance with this invention can be obtained from the transgenic animal, and stored under conditions effective for later use, as is known 20 in the art. The invention will now be described in greater detail by reference to the following non-limiting examples. The pertinent portions of the contents of all references, and published patent applications cited throughout this patent necessary for enablement purposes are hereby incorporated by reference. 25 EXAMPLES GENETIC MODIFICATION OF MALE GERM CELLS IN VIVO AND IN VITRO In Vivo Adenovirus-enhanced Transferrin-polylysine-mediated Delivery of Green Lantern Reporter Gene Delivery System to Testicular Cells The adenovirus enhanced transferrin-polylysine-mediated gene delivery system has been 30 described and patented by Curiel et al. (Curiel D.T.,et al., Adenovirus enhancement of transferrin polylysine-mediated gene delivery, PNAS USA 88: 8850-8854 (1991). The delivery of DNA depends upon endocytosis mediated by the transferrin receptor (Wagner et al., Transferrin-polycation conjugates as carriers for DNA uptake into cells, PNAS (USA) 87: 3410-3414 (1990). In addition WO 00/69257 PCT/USOO/13000 28 this method relies on the capacity of adenoviruses to disrupt cell vesicles, such as endosomes and release the contents entrapped therein. This system can enhance the gene delivery to mammalian cells by as much as 2,000 fold over other methods. The gene delivery system employed for the in vivo experiments was prepared as shown in 5 examples below. Example 1: Preparation of Transferrin-poly-L-Lysine Complexes Human transferrin was conjugated to poly (L-lysine) using EDC (1-ethyl-3-(3- dimethyl aminopropyl carbodiimide hydrochloride) (Pierce), according to the method of Gabarek and Gergely (Gabarek & Gergely, Zero-length cross-linking procedure with the use of active esters, Analyt. 10 Biochem 185 : 131 (1990)). In this reaction, EDC reacts with a carboxyl group of human transferrin to form an amine-reactive intermediate. The activated protein was allowed to react with the poly (L-lysine) moiety for 2 hrs at room temperature, and the reaction was quenched by adding hydroxylamine to a final concentration of 10 mM. The conjugate was purified by gel filtration, and stored at -20'C. .5 Example 2: Preparation of DNA for In Vivo Transfection The Green Lantern-I vector (Life Technologies, Gibco BRL, Gaithersberg, MD) is a reporter construct used for monitoring gene transfection in mammalian cells. It consists of the gene encoding the Green Fluorescent Protein (GFP) driven by the cytomegalovirus (CMV) immediate early promoter. Downstream of the gene is a SV40 polyadenylation signal. Cells transfected with Green Lantern-1 20 fluoresce with a bright green light when illuminated with blue light. The excitation peak is 490 nm. Example 3: Preparation of Adenoviral Particles Adenovirus d1312, a replication-incompetent strain deleted in the Ela region, was propagated in the Ela trans-complementing cell line 293 as described by Jones and Shenk (Jones and Shenk, PNAS USA (1979) 79: 3665-3669). A large scale preparation of the virus was made using the method 25 of Mittereder and Trapnell (Mittereder et al., "Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy", J. Urology, 70: 7498-7509 (1996)). The virion concentration was determined by UV spectroscopy, 1 absorbance unit being equivalent to 10 viral particles /ml. The purified virus was stored at -70'C. Example 4: Formation of Transferrin-voly-L 30 Lysine-DNA-Viral Complexes Six (6) micrograms of transferrin-polylysine complex from Example 1 were mixed in 7.3 x 107 adenovirus d1312 particles prepared as in Example 3, and then mixed with 5 pg of the Green WO 00/69257 PCT/USOO/13000 29 Lantern DNA construct of Example 2, and allowed to stand at room temperature for 1 hour. About 100 pl of the mixture were drawn up into a micropipette, drawn on a pipette puller, and slightly bent on a microforge. The filled micropipette was then attached to a picopump (Eppendorf), and the DNA complexes were delivered under continuous pressure, in vivo to mice as described in Example 6. 5 Controls were run following the same procedure, but omitting the transferrin-poly-lysine-DNA-viral complexes from the administered mixture. Example 5: Comparison of Adenovirus-enhanced Transferrin-polylysine & Lipofectin Mediated Transfection Efficiency The conjugated adenovirus particle complexed with DNA were tested on CHO cells in vitro 0 prior to in vivo testing. For these experiments a luciferase reporter gene was used due to the ease of quantifying luciferase activity. The expression construct consists of a reporter gene encoding luciferase, is driven by the CMV promoter (Invitrogen, Carlsbad, CA 92008). CHO cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum. For gene transfer experiments CHO cells were seeded into 6 cm tissue culture plates and grown to about 50% 5 confluency (5x 10' cells). Prior to transfection the medium was aspirated and replaced with serum free DMEM. Cells were either transfected with transferrin-polylysine-DNA complexes or with lipofectin DNA aggregates. For the transferrin-polylysine mediated DNA transfer, the DNA-adenovirus complexes were added to the cells at a concentration of 0.05-3.2 x 104 adenovirus particles per cell. Plates were returned to the 5% CO 2 incubator for 1 hour at 37 C. After 1 hour 3 ml of complete media 20 was added to the wells and the cells were allowed to incubate for 48 hours before harvesting. The cells were removed from the plate, counted and then lysed for measurement of luciferase activity. For cells transfected by lipofectin, 1ptg of CMV-luciferase DNA was incubated with 17tl of Lipofectin (Life Technologies). The DNA-lipofectin aggregates were added to the CHO cells and allowed to incubate at 37 0 C at 5% CO 2 for 4 hours. Three milliliters of complete medium was added 25 then to the cells and they were allowed to incubate for 48 hours. The cells were harvested, counted and lysed for luciferase activity. The luciferase activity was measured by a luminometer. The results obtained are shown in Table 1. The data included in Table 1 below show that the adenovirus-enhanced transferrin-polylysine gene delivery system is 1,808 fold more efficient than lipofection for transfection of CHO cells.
WO 00/69257 PCT/USOO/13000 30 Table 1: Comparison of Lipofection & Adenovirus Enhanced Transferrin-polylysine Transfection of CHO Cells Sample Treatment Luci ferase Activity (RLU) 5 1 1x107 particles + 6ug CMV-Luc 486 2 2.5 x 107 particles + 6ug CMV-Luc 1201 3 5.0 x 107 particles + 6ug CMV-luc 11119 4 1 x 109 particles + 6ug CMV-Luc 2003503 0 5 Lipofection 1108 6 Unmanipulated cells 155 Example 6: In Vivo Delivery of DNA to Animal's Germ Cells via Transferrin-L-lysine-DNA-Viral Complexes 5 The GFP DNA-transferrin-polylysine viral complexes, prepared as described in Example 4 above, were delivered into the seminiferous tubules of three (3)-week-old B6D2F1 male mice. The DNA delivery by transferrin receptor-mediated endocytosis is described by Schmidt et al. and Wagner et al. (Schmidt et al., Cell 4: 41-51 (1986); Wagner, E., et al. PNAS (1990), (USA) 81: 3410-3414 [1990]). In addition, this delivery system relies on the capacity of adenoviruses to disrupt cell vesicles, !0 such as endosomes and release the contents entrapped therein. The transfection efficiency of this system is almost 2,000 fold higher than lipofection. The male mice were anesthetized with 2% Avertin ( 100% Avertin comprises 10 g 2,2,2 tribromoethanol (Aldrich) and 10 ml t-amyl alcohol (Sigma), and a small incision made in their skin and body wall, on the ventral side of the body at the level of the hind leg. The animal's testis was 25 pulled out through the opening by grasping at the testis fat pad with forceps, and the vas efferens tubules exposed and supported by a glass syringe. The GFP DNA-transferrin-polylysine viral complexes were injected into a single vasa efferentia using a glass micropipette attached to a hand held glass syringe or a pressurized automatic pipettor (Eppendorf), and Trypan blue added to visualize the entry of the mixture into the seminiferous tubules. The testes were then placed back in the body 30 cavity, the body wall was sutured, the skin closed with wound clips, and the animal allowed to recover on a warm pad. Example 7: Detection of DNA and Transcribed Messa2e Nine (9) days after delivery of the genetic material to the animals' testis, two of the animals were sacrificed, their testes removed, cut in half, and frozen in liquid nitrogen. The DNA from one 35 half of the tissues, and the RNA from the other half of the tissues were extracted and analyzed.
WO 00/69257 PCT/USOO/13000 31 (a) Detection of DNA The presence of GFP DNA in the extracts was tested 9 days after administration of the transfection mixture using the polymerase chain reaction, and GFP specific oligonucleotides. GFP DNA was present in the testes of the animals that had received the DNA complexes, but was absent 5 from sham operated animals. (b) Detection of RNA The presence of GFP mRNA was assayed in the testes of experimental animals as follows. RNA was extracted from injected, and non-injected testes, and the presence of the GFP messages was detected using reverse transcriptase PCR (RT PCR) with GFP specific primers. The GFP message 10 was present in the injected testes, but not in the control testes. The DNA detected above by PCR analysis is episomal GFP DNA. The transfected gene was being transiently expressed. Example 8: Expression of Non-endogenous DNA Two males, one having received an injection with the GFP transfection mixture and a control to whom only surgery was administered, were sacrificed 4 days after injection, and their testes excised, 15 and fixed in 4% paraformaldehyde for 18 hours at 4'C. The fixed testis was then placed in 30% sucrose in PBS with 2 mM MgCl 2 for 18 hours at 4'C, embedded in OCT frozen on dry ice, and sectioned. When the testes of both animals were examined with a confocal microscope with fluorescent light at a wavelength of 488 nM, bright fluorescence was detected in the tubules of the GFP-injected mice, but not in the testes of the controls. Many cells within the seminferous tubules 20 of the GFP-injected mouse showed bright fluorescence, which evidences that they were expressing Fluorescent Green Protein. Example 9: Generation of Offspring from Normal Matings GFP transfected males were mated with normal females. The females were allowed to complete gestation, and the pups to be born. The pups (F1 offspring or progeny) were screened for 25 the presence of the novel genetic material(s). Example 10: In Vitro Transfection of Testicular Cells Cells were isolated from the testes of three 10-day-old mice. The testes were decapsulated and the seminiferous tubules were teased apart and minced with sterile needles. The cells were incubated in enzyme mixture for 20 minutes at 37 C. The enzyme mixture was made up of 10 mg bovine serum 30 albumin (embryo tested), 50 mg bovine pancreatic trypsin type III, Clostridium collagenase type I, 1 mg bovine pancreatic DNAse type I in 10 mis of modified HTF medium (Irvine Scientific, Irvine, CA). The enzymes were obtained from Sigma Company (St. Louis, Missouri 63178). After digestion, the WO 00/69257 PCT/USOO/13000 32 cells were washed twice by centrifugation at 500 x g with HTF medium and resuspended in 250pl HTF medium. The cells were counted, and 0.5 x 106 cells were plated in a 60mm culture dish in a total volume of 5ml DMEM (Gibco-BRL, Life Technologies, Gaithesburg, MD 20884). A transfection mixture was prepared by mixing 5p1g Green Lantern DNA (Gibco-BRL, Life Technologies, 5 Gaithesburg, MD 20884) with 20/A Superfect (Qiagen, Santa Clarita, CA 91355) and 150pl DMEM. The transfection mix was added to the cells and they were allowed to incubate for 3 hours at 37"C, 5%
CO
2 The cells were transferred to a 33"C incubator and incubated overnight. The following morning the cells were assessed for transfection efficiency by counting the number of fluorescent cells. In this experiment the transfection efficiency was 90% (Figure not 10 shown). The testicular cells transfected with Green Lantern viewed with Nomaski optics x20 show the same cells viewed with FITC. Nearly all the cells were fluorescent, which is confirmation of their successful transfection. Example 11: Preparation of a Cell Suspension from Testicular Tissue for Cryopreservation A cell suspension was prepared from mice of different ages as described below. 15 Group I: 7-10 day olds Group II: 15-17 day olds Group III: 24-26 day olds The mice's testes were dissected, placed in phosphate buffered saline (PBS) decapsulated, and the seminiferous tubules were teased apart. Seminiferous tubules from groups I and II were transferred 20 to HEPES buffered culture medium (D-MEM) (Gibco-BRL, Life Technologies, Gaithersberg, MD 20884) containing 1mg/mi Bovine serum albumin (BSA) (Sigma, St. Louis, MO 63178) and Collagenase Type I (Sigma) for the removal of interstitial cells. After a 10 minute incubation at 33'C, the tubules were lifted into fresh culture medium. This enzymatic digestion was not carried out on the testes from group I because of their fragility. 25 The tubules from group II and III mice or the whole tissue from group I mice were transferred to a Petri dish with culture medium and were cut into 0.1-1mm pieces using a sterile scalpel and needle. The minced tissue was centrifuged at 500 x g for 5 minutes and the pellet was resuspended in imil of enzyme mix. The enzyme mix was made up in D-DMEM with HEPES (Gibco-BRL) and consisted of 1mg/mi bovine serum albumin (BSA) (Sigma, embryo tested), 1mg/ml collagenase I 30 (Sigma) and 5 mg/mi bovine pancreatic trypsin (Sigma) and 0.1mg/mil deoxyribonuclease I (DN-EP, Sigma). The tubules were incubated in enzyme mix for 30 minutes at 33'C. After the incubation, 1mi of medium was added to the mix and the cells were centrifuged at 500 x g for 5 min. The cells were washed twice in medium by centrifugation and resuspension. After the final wash the cell pellet was resuspended in 250ptl of culture medium and counted. 35 WO 00/69257 PCTIUSOO/13000 33 Example 12: Transferring Transfected Male Germ Cells Into Recipient Testis The cells were injected into the testis via the vasa efferentia using a micropipette. 3 x I0 cells in a total volume of 50ptl were used for the injection. The cells were mixed with Trypan blue prior to the injection. The recipient mice were anesthetized with 0.0 17mL/g body wt. Avertin. An incision 5 was made across the lower abdominal wall and the testis was gently pulled to the exterior through the incision by pulling on the fat pad associated with the testis. The vas efferens was exposed and approximately 20 ktL of cell suspension was injected into the vas efferens using a glass micropipette held in a steel micropipette holder (Leitz). The cells were expelled from the pipette using air pressure from a 20 mL glass syringe. Prior to the transfer of transfected germ cells to the recipient animals, the 10 recipient testes were depopulated of endogenous male germ cells. Example 13: Depopulating the Recipient Testis of Male Germ Cells. Comparison of Depopulating Treatments. Eight-week-old C57BL/6J mice were allowed to acclimatize for a few days and then were assigned to one of the following three treatment groups. They received: (1) 400 Rad gamma irradiation; (2) 4 yG/g body weight of busulfan (1,4-butanediol 15 dimethanesulphonate; Myleran, Glaxo Wellcome); or (3) a combination treatment of busulfan (4yug/g body wt) followed one week later by 400 Rad of gamma irradiation ("busulfan/400 Rad" treatment). A fourth group of untreated C57BL/6J mice of the same age as the treatment groups was used as a control. There were 24 mice in each treatment group, and 3 mice were mice sacrificed at each of the following time intervals after treatment: 5 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 1 20 month and 2 months after treatment. In addition, other C57BL/6J mice receiving the combined busulfan/400 Rad treatment were examined histologically at time points up to five months after treatment (the testes of these other mice were fixed overnight in 4% paraformaldehyde in PBS, pH 7.4 at 4'C, dehydrated and embedded in paraffin before sectioning and H&E staining). 25 Delivery of an Alkylating Agent to Recipient Vertebrates. The male mice receiving busulfan received a dose of 4 pg busulfan per g body wt. The busulfan was first dissolved 8mg/mL in 100% dimethyl sulfoxide (DMSO) then, immediately before injection, was diluted 1:1 in phosphate buffered saline, pH 7.4. The mice were injected with the diluted busulfan solution intraperitoneally. Irradiation Treatment of Recipient Vertebrates. For the gamma irradiation treatment, mice were 30 anesthetized with 0.017 mL/g body wt. of 2.5% Avertin. Gamma irradiation was specifically directed to the testis in the following manner. Each mouse was placed in a lead chamber with only the testis and lower abdomen exposed through elliptical holes to the irradiating source (1 3 7 Cs Gammacell 40 irradiator [Nordion]). There were six aligned holes in the floor and roof of the chamber through which WO 00/69257 PCT/USOO/13000 34 the gamma radiation passed unobstructed. After irradiation the animals were allowed to recover from the anesthesia on a warm heating pad or water bed until they regained consciousness. Histology. At selected time points, mice from each treatment group were euthanized, and testicular tissues to be examined were fixed in 10% formalin in PBS, pH 7.4, at 4'C for 24 hours. Small slits 5 in the testis capsule were made to allow penetration of the fixative. Fixed samples were washed four times with PBS, and embedded in paraffin using a Tissue Tek-II tissue processor (MET). Sections of 8 ym thickness were cut, stained with haemotoxylin and eosin (H&E), and mounted with Aquamount (Lerner Laboratories) on glass slides with coverslips. The sections were viewed on a Zeiss or Olympic light microscope with a 40X objective lens (total magnification 400X). 10 Quantitative Histologic Analysis. Quantitative data were collected from the testes of two animals for each of the treatment groups at two months after treatment. (Table 2). For the control group only one mouse was used. The seminiferous tubules in a single section were counted using a 5X objective on a Zeiss light microscope (50x total magnification). Individual seminiferous tubules were examined at 400X total magnification. Seminiferous tubules were considered severely damaged if hardly any 15 cells remained in the tubule, and the tubule consisted of a basement membrane with a single layer of cells, mostly spermatogonia, lying along the basement membrane. Moderately damaged tubules were tubules, in which some of the spermatogenic layers close to the lumen were partially sloughed off. Spermatozoan heads were counted in the tubules and averaged over the total number of tubules counted. 20 Results of Histological Analysis. Obvious histological changes were not seen in the testis until two weeks after treatment. (Data no shown). After two weeks changes included severe disruption of spermatogenesis; all the mature spermatozoa were lost and no spermatids or spermatocytes were present. A few Sertoli cell nuclei and spermatogonia were detectable in the periphery along the basement membrane. Six weeks after busulfan/400 Rad treatment there was evidence of the re 25 establishment of spermatogenesis. Some spermatids and spermatozoa were seen as well as a few spermatocytes. By about 3 months most of the seminiferous tubules had at least partially recovered and all stages of spermatogenesis appear to be represented. (Data not shown). Spermatogenesis had returned to normal at this stage by five months after busulfan/400 Rad treatment. 30 The three treatment groups described above were also compared. The most dramatic differences among the groups were seen at two months after treatment. At two months the mice that were treated with the combined busulfan/400 Rad gamma irradiation treatment showed the greatest number of substantially depopulated seminiferous tubules. Seminiferous tubules from this group also WO 00/69257 PCT/USOO/13000 35 contained a smaller average number of sperm heads per seminiferous tubule and the greatest proportion of severely and moderately damaged seminiferous tubules compared to the other treatment groups and the control mice. (Table 2). Treatment of the mice with either 400 Rad gamma irradiation or busulfan alone also resulted in damage to the spermatogenic process, including sloughing of cells 5 into the lumen of the tubule, and substantially fewer mature spermatozoan heads compared to the controls, but to a significantly lesser extent than exemplified by the busulfan/400 Rad treatment group. These results clearly demonstrate that a combination of treatment with an alkylating agent and gamma irradiation is a more effective method of depopulating a vertebrate testis of male germ cells than either of the two treatments alone. 10 Table 2. Comparison of Various Methods of Depopulating a Vertebrate Testis of Male Germ Cells. No. Tubules No. Severely No. Moderately Total No. Sperm Average Treatment Counted damaged damaged heads No. sperm heads/tu bule Control 50 0 0 1733 in 50 tubules 35 Busulfan/ 50 15 (30%) 3 (6%) 460 in 50 tubules 9 400 R 1 15 Busulfan/ 57 14 (24%) 8 (14%) 383 in 50 tubules 8 400R Busulfan 70 1 (1%) 5 (7%) 957 in 50 tubules 19 Busulfan 69 3 (10%) 2 (3%) 764 in 50 tubules 15 400R 52 2 (4%) 1 (2%) 1005 in 50 tubules 20 20 400R 41 2 (5%) 3 (7%) 827 in 41 tubules 20 Example 14: In vivo Transduction Using a Viral Vector A retroviral vector was used to transduce (genetically alter or modify) male germ cells of mice in vivo. Specifically, a pseudo-typed HIV-derived viral vector (L. Naldini et al., In vivo gene delivery and stable transduction of nondividing cells by a Lentiviral vector, Science 272:263-67 [1996]), was 25 used, as modified by Carlos Lois to express Green Flourescent Protein (GFP) instead of the LacZ reporter gene, under the transcriptional control of the CMV promoter (HR'GFP). Recipient C57BL/6J mice were treated with busulfan 44 days prior to viral infection. C57BL/6J male mice were injected intraperitoneally with 0.1 ml busulfan at a concentration of 1 WO 00/69257 PCTIUSOO/13000 36 mg/ml. The dose was 4 ptg busulfan/gm body wt. One pretreated mouse was anesthetized with Avertin (0.017mis/gm body wt.), and a ventral midline incision was made and the right testis exposed. The vas efferentia were dissected away from the fat, and ten microlitres of HIV-derived GFP vector, HR'GFP, at a titer of 1x10 9 particles/ml were injected into the seminiferous tubules of the right 5 testis via the vas efferens of a busulfan-treated C57 BL/6J mouse. Injection was done with a quartz glass micropipette attached to a Picospritzer Il. The Picospritzer was set at 80psi and gave 1 second bursts upon manual depression of a foot pedal. All the seminiferous tubules of the testis can be reached with a single injection as the vas efferens leads to a common chamber, the rete testis, from which all the tubules radiate. The left testis was not injected and was used as a control. Transduction 10 of the testicular cells within the tubules was widespread. Twenty one days after infection, the mouse was sacrificed and the testes were fixed overnight in 4% paraformaldehyde in PBS, pH 7.4 at 4'C. The testes were washed three times in PBS and placed in 20% sucrose overnight at 4'C. The testes were frozen in OCT and sectioned at 8ptm on a cryostat. The sections were thawed to room temperature immersed in phosphate saline buffer and 15 viewed on a Zeiss 310 confocal microscope. The laser was set at a wavelength of 488 nm. Green fluorescence was seen in all the seminiferous tubules that were viewed, although the intensity was greatest in the tubules at the surface of the testis. Transduction was seen in the Sertoli support cells as well as in the spermatogonia along the basement membrane, but little was seen in the spermatocytes or spermatids. Very few mature spermatozoa were present due to the Busulfan 20 treatment. No fluorescence was seen in the left testes used as control. This shows that male germ cells can be transduced by a viral vector and that the transduced gene is expressed. Example 15: Optimization Microinjection of Gene Delivery Mixture through the Vas Efferens. The method of delivery (Winston, R.M.L., Microsurgical reanastomosis of the rabbit oviduct and its functional and pathological sequelae, Brit. J. Obstet. Gynaecol. 82:513 - 522 ([1975]) of viral 25 particles into a single vas efferens, and thence to the seminiferous tubules, was first optimized in several mice (Figs la-ld). The mice were treated with busulfan (Myleran: Glaxo Wellcome) 14 days before microsurgery to maximize the chance of viral particles gaining access to spermatogonia, which lie on the basement lamella of the tubules. Busulfan, an alkylating cytotoxic agent, depopulates the testis (Bucci, L. and Meistrich, M., Effects of busulfan on murine spermatogenesis: cytotoxicity, 30 sterility, sperm abnormalities, and dominant lethal mutations, Mut. Res. 176:259-268 [1987]). At the intraperitoneal (IP) dose given (4pg/g body wt.) many of the spermatocytes, spermatids and spermatozoa were eliminated from the tubules, but the testis recovered three to four months afterward and fertility was restored. This implies that stem cells remain viable and can repopulate the testis. Stem cell spermatogonia are known to be resistant to insults, often surviving when other germ cell WO 00/69257 PCT/USOO/13000 37 types are destroyed (Huckins, C. & Oakberg, W.F., Morphological and quantitative analysis of spermatogonia in mouse testes using whole mounted seminiferous tubules. II. The irradiated testes, Anat. Rec. 192:529-42 [1978]). Example 16: Production of Transgenic Progeny by In Vivo Transduction of Male Germ Cells 5 Followed by Natural Mating Microsurgery. After depopulation of the testis as described in Example 15, viral particles were delivered to the seminiferous tubules as follows: Mice were anaesthetised with isofluorane (0.5-2% in oxygen). Each testis was exposed through a midline abdominal incision. Using a microsurgical approach (Winston [1975]; Zeiss microscope at magnification 4 to 50x) the tissue bundle containing 10 the vasa efferentia was visualised (Fig la-1b). Dissection from the surrounding fat was aided by a stream of phosphate buffered saline forced through a fine needle. A quartz glass micropipette was back-filled with 10 pL viral particles (10 9 pfu/ml) mixed with 1 yL polybrene (80mg/mL). This was attached to a micropipette (Eppendorf) and the particles introduced into the vas efferens under 2.2 bar pressure in pulses of 1.5 seconds, controlled by foot pedal. Earlier trials using 1% Bromophenol dye 15 showed that most seminiferous tubules could be filled (Fig. 1c), but during treatments, no dye was used and small air bubbles were introduced into the liquid containing viral particles to confirm dispersion into the seminiferous tubules (Fig. 1d). To preserve fertility, only single vasa efferentia were injected, reducing injury to the remaining ducts. Preparation of the Viral Vector. The plasmid, pHR'-CMVLacZ (L. Naldini et al. [1996]), was 20 modified by replacing the BamHI - XhoI fragment containing the LacZ gene with a fragment containing the EGFP gene ('humanised' GFP, Clontech). For the production of viral particles 40 pg plasmid DNA was used to transfect a 10-cm plate of 293T cells. The 40 ptg of plasmid DNA was made up of 10 pug pCMV R9, 20pg of modified pHR' and 10 pg envelope plasmid. Vesicular-stomatitis-virus-glycoprotein (VSV-G) pseudotyped vectors were produced by 25 contransfection of the vector plasmid with the Moloney murine leukemia virus (MLV) gag-pol packaging plasmid pCMV-GAGPOL and the VSV-G plasmid. The supernatant was harvested 48-60 hours after transfection, subjected to high speed centrifugation, filtered through 0.45 pm filters and assayed. The transducing viral particles had the MLV restricted envelope protein, env, substituted with a broad-spectrum env protein from the vesicular stomatitis virus.
WO 00/69257 PCT/USOO/13000 38 In Vivo Transduction of Male Germ Cells. Six mice were now treated with viral particles containing the transducing vector pHR' (10 9 particles/mL). A single vas efferens was injected with a volume of lOpL retroviral concentrate together with 1 piL (80mg/mL) polybrene. After 24 days the mice were sacrificed and the testes removed and fixed for cryosectioning and histological 5 examination. Testes were fixed for 48 hours in 4% Paraformaldehyde pH 7.4, and placed in 20% sucrose in phosphate saline buffer pH 7.4 at 4'C for 24 hours. They were embedded in OCT and stored at -70'C. They were cryosectioned at 8im and viewed in a Zeiss 410 confocal microscope (Fig. 2). Nearly all tubules sectioned contained cells expressing GFP. Expression was highest in 10 Sertoli and spermatogonia cells (Fig. 2a -b). Natural Matings with Females after Transduction of Male Germ Cells. Eleven C57/B 1/6J young males were then selected to test whether transduced male germ cells could transmit the retrovirally integrated transgene to the next generation. Six of these mice were treated with a 15 bolus of busulfan (IP; 4pg/gm body wt.) 14 days before in vivo transduction microsurgery in accordance with the in vivo method of incorporating exogenous genetic material into the genome of a vertebrate, as described above, and three received the same dose only one week before in vivo transduction. Two other mice were not pre-treated with busulfan before the in vivo transduction operation. Lentiviral particles were introduced into the seminiferous tubules. After 20 14 weeks, B6D2F1 females were introduced into cages with the males. Transduced males fathered at least two successive litters. Litters were conceived 14, 15, 19 and 20 weeks after transduction. All the males, except one dying immediately after surgery, fathered transgenic offspring. (Table 3).
WO 00/69257 PCT/USO0/13000 39 Table 3. Production of transgenic offspring per litter fathered by treated males at various times after mating. Mouse # Pre-treatment 14 weeks 15 weeks 19 weeks 20 weeks 1 Busulfan 1 week - 2/9 (22%) 8/10 (90%) 0/9 (0%) 5 2 Busulfan 1 week - 1/7 (14%) 1/7 (14%) 2/7 (28%) 3 Busulfan 1 week 4/7 (57%) 1/8 (12%) 4/6 (66%) 0/7 (0%) 4 Busulfan 1 week 7/8 (87%) 3/7 (43%) 1/6 (17%) 1/8 (12%) 5 Busulfan 2 weeks 5/6 (83%) 8/9 (89%) - 0/8 (0%) 6 Busulfan 2 weeks - 2/8 (25%) 8/8 (100%) 1/9 (11%) 10 7* Busulfan 2 weeks - 8 Busulfan 2 weeks - 6/6 (100%) - 1/8 (12%) 9 Busulfan 2 weeks - 8/8 (100%) - 3/10 (30%) 10** none 2/5 (40%) 5/6 (83%) 11 none 3/7 (43%) 7/8 (88%) - 0/6 (0%) 15 *Mouse No. 7 died immediately after surgery; **Mouse No. 10 died 17 weeks after surgery. PCR and Southern blot analysis of DNA from embryonic offspring. Embryos at approximately embryonic day 12.5, were screened for presence of the transgene by polymerase chain reaction (PCR) and Southern blot analysis. For the PCR, GFP specific primers were used and a 20 radiolabeled GFP cDNA probe was used for the Southern blot analysis (Fig. 3). DNA was purified from embryos using the Gentra purification system. The presence of the transgene was ascertained using PCR amplification with the following GFP specific primers: (A) forward primer: 5'-GGT GAG CAA GGG CGA GGA GCT-3' (SEQ. ID. NO.: 1) (B) reverse primer: 5'-TCG GGC ATG GCG GAC TTG AAG A-3' (SEQ. ID. NO.:2) 25 The PCR cycling conditions were: denaturing 94'C for 1 minute, annealing at 60'C for 1 minute and extension at 72'C for 3 minutes. PCR ran for 35 cycles and yielded a specific GFP product 470 base pairs in length. Each cycle step can be reduced to one second - "one second PCR" to yield a distinct 470-bp PCR amplification product. Southern blot analysis was also done on the same embryo DNA extracts. The DNA was cut with BamHl-Xhol, run on a 0.8% agarose gel and 30 blotted overnight in 20x SSC onto Hydrobond XL paper. The blots were hybridised overnight at 65'C with a 32 P-radiolabeled BamHI-XhoI GFP fragment isolated from the pHR'plasmid. The blots were washed at 65'C (30 minutes) each in 2x SSC with 0.1% SDS, 1x SSC with 0.1% SDS, 0.1 X SSC with 0.1% SDS and exposed to X-ray film.
WO 00/69257 PCT/USO0/13000 40 PCR and Southern analysis showed that a high percentage of transgenic offspring were obtained in litters conceived within 15 weeks. The results are summarized in Table 3. By 20 weeks the percentage of transgenic progeny had dropped in all of the treatment groups, implying that the self-renewing spermatogonia were not transduced, but rather a population of 5 differentiating spermatogonia. Once the daughter cells from this population had matured and left the testis they were not renewed (Huckins, C. & Oakberg, W.F. [1978]). In Table 3, the ratios are the number of transgenic offspring out of the total number of embryos in the litter. Although pre-treatment with busulfan enhanced the transduction of spermatogonia, mice untreated with busulfan also generated transgenic offspring. Male germ cells take 60 days to 10 differentiate from spermatogonia (Russell, L.D., et al. In: Histological and Histopathological evaluation of the testis, Cache River Press [1990]), undergo meiosis and form spermatozoa. Since conception was more than 60 days after transduction, it is presumed that the transgenic offspring were conceived from differentiated daughter cells of transduced spermatogonia. EGFP expression was driven by the CMV promoter and was evident in the testicular cells of the founder 15 males 24 days after infection. The animals that were infected did not appear to have toxic side effects (Verma, I.M. and Somia, N. [1997]) with the possible exception of one dying 17 weeks after surgery. The foregoing examples being illustrative but not an exhaustive description of the embodiments of the present invention, the following claims are presented.
Claims (60)
1. An in vivo method of incorporating exogenous genetic material into the genome of a vertebrate, said method comprising: administering to a male vertebrate's testis a gene delivery mixture comprising a viral vector that comprises at least one polynucleotide encoding a desired trait or product, said polynucleotide being operatively linked to a promoter sequence such that a transcriptional unit is formed, under conditions effective to reach a spermatozoan or precursor cell within the testis, said precursor cell being selected from the group consisting of spermatogonial stem cells, type B spermatogonia, primary spermatocytes, preleptotene spermatocytes, leptotene spermatocytes, zygotene spermatocytes, pachytene spermatocytes, secondary spermatocytes, and spermatids; incorporating the polynucleotide encoding a desired trait or product into the genome of the spermatozoan cell or the precursor cell, so that a genetically modified male gamete is produced by the male vertebrate; and breeding the male vertebrate with a female vertebrate of its species such that a transgenic progeny is thereby produced that carries the polynucleotide in its genome.
2. An in vitro method of incorporating at least one polynucleotide encoding a desired trait into the genome of a vertebrate, comprising: obtaining from a donor male vertebrate a spermatozoan cell or a precursor cell selected from the group consisting of spermatogonial stem cells, type B spermatogonia, primary spermatocytes, preleptotene spermatocytes, leptotene spermatocytes, zygotene spermatocytes, pachytene spermatocytes, secondary spermatocytes, and spermatids; genetically modifying the spermatozoan cell or precursor cell in vitro with a polynucleotide encoding a desired trait or product other than an immortalizing molecule, and a gene encoding a genetic selection marker, in the presence of a gene delivery mixture comprising a viral vector, at about or below the vertebrate's body temperature and for an effective period of time such that the polynucleotides are incorporated into the genome of the cell; isolating or selecting the genetically modified cell with the aid of the genetic selection marker expressed in the genetically modified cell; transferring the thus isolated or selected genetically modified cell to a testis of a recipient male vertebrate such that the cell lodges in a seminiferous tubule of the testis and a genetically modified male gamete is produced therein; and breeding the recipient male vertebrate with a female vertebrate of its species such that a transgenic progeny is thereby produced that carries the polynucleotide in its genome. WO 00/69257 PCT/USOO/13000 42
3. The method of claim 2, wherein the gene delivery mixture further comprises a transfecting agent selected from the group consisting of liposomes, lipid transfecting agents, transferrin-polylysine enhanced viral vectors, retroviral vectors, and lentiviral vectors, or comprises a mixture of any members of said group.
4. The method of Claim 2, wherein the polynucleotide encoding a desired trait or product is expressed in said cell from a germ cell-specific promoter.
5. The method of Claim 2, wherein the polynucleotide encoding a desired trait or product is in the form of a complex with the viral vector.
6. The method of Claim 3, wherein the transfecting agent comprises a lipid transfecting agent.
7. The method of Claim 2, wherein the transfecting agent further comprises a male germ-cell-targeting molecule.
8. The method of Claim 7, wherein the male-germ-cell-targeting molecule comprises a c-kit ligand; and the genetic selection marker comprises a gene expressing a detectable product, transcribed from a spermatogonia-specific promoter selected from the group consisting of c-kit promoter, b-Myb promoter, c-raf-1 promoter, vasa promoter, ATM promoter, RBM promoter, DAZ promoter, XRCC-1 promoter, cyclin Al promoter, HSP 90 promoter, and FRMI promoter.
9. The method of Claim 2, wherein the gene encoding a genetic selection marker is expressed from a germ cell-specific promoter.
10. The method of any of Claims lor 2, wherein the viral vector is selected from the group consisting of retroviral vectors, adenoviral vectors, transferrin-polylysine enhanced adenoviral vectors, human immunodeficiency virus vectors, lentiviral vectors, Moloney murine leukemia virus-derived vectors, mumps vectors, and virus-derived DNAs that facilitate polynucleotide uptake by and release into the cytoplasm of germ cells, or comprises a mixture of any members of said group. WO 00/69257 PCTIUSOO/13000 43
11. The method of any of Claims 1 or 2, wherein the viral vector is a retroviral vector, and the polynucleotide encoding a desired trait or product is expressed in one or more cells of the progeny.
12. The method of Claim 11, wherein the retroviral vector is a Moloney murine leukemia virus-derived vector or pseudotyped lentiviral vector.
13. An in vivo method of incorporating exogenous genetic material into the genome of a vertebrate, said method comprising: administering to a male vertebrate's testis a gene delivery mixture comprising a retroviral vector that comprises at least one polynucleotide encoding a desired trait or product and optionally a gene encoding a genetic selection marker, operatively linked to a promoter sequence such that a transcriptional unit is formed, under conditions effective to reach within the testis a spermatozoan cell or a precursor cell selected from the group consisting of spermatogonial stem cells, type B spermatogonia, primary spermatocytes, preleptotene spermatocytes, leptotene spermatocytes, zygotene spermatocytes, pachytene spermatocytes, secondary spermatocytes, and spermatids; incorporating the polynucleotide encoding a desired trait or product into the genome of the spermatozoan cell or the precursor cell, so that a genetically modified male gamete is produced by the male vertebrate; and breeding the male vertebrate with a female of its species such that a transgenic progeny is produced thereby that carries the polynucleotide in its genome.
14. The method of Claim 13, wherein the retroviral vector is a Moloney murine leukemia virus-derived vector or pseudotyped lentiviral vector.
15. The method of any of Claims 1, 2 or 13, wherein breeding is accomplished by natural mating of the male vertebrate and female vertebrate.
16. The method of Claim 1 or Claim 13, wherein the viral vector further comprises a gene encoding a genetic selection marker operatively linked to a male germ cell-specific promoter.
17. The method of any of Claims 1, 2 or Claim 13, wherein breeding is accomplished by artificial insemination of the female vertebrate with semen comprising the genetically modified male gamete. WO 00/69257 PCT/USOO/13000 44
18. The method of any of Claims 1, 2 or 13, wherein breeding is accomplished by in vitro fertilization of an ovum of the female vertebrate with the genetically modified male gamete.
19. The method of any of Claims 1, 2 or 13, wherein breeding is accomplished by intracytoplasmic sperm injection, subzonal insemination, or partial zona dissection resulting in fertilization of an ovum of the female vertebrate with the genetically modified male gamete.
20. The method of any of Claims 1, 2 or 13, further comprising raising the transgenic progeny to sexual maturity.
21. The method of Claim 20, further comprising breeding the sexually mature transgenic progeny with a member of the opposite sex of its species so that a second or subsequent generation of transgenic progeny is produced.
22. The method of Claim 21, wherein the vector comprises a genetic selection marker operatively linked to a promoter sequence and transgenic progeny of a second or subsequent generation are identified by the expression of the genetic selection marker in one or more cells thereof.
23. The method according to any of Claims 1 or 13, wherein the gene delivery mixture is administered into the vertebrate's testis by percutaneous injection.
24. The method according to Claims 1 or 13, wherein the gene delivery mixture is directly administered into the vertebrate's vas efferens.
25. The method according to any of Claims 1 or 13, wherein the gene delivery mixture is directly administered into a seminiferous tubule of the vertebrate's testis.
26. The method according to any of Claims 1 or 13, wherein the gene delivery mixture is directly administered into the rete of the vertebrate's testis.
27. The method of any of Claims 1, 2, or 13, wherein the polynucleotide encoding a desired trait or product is operatively linked to a constitutive promoter.
28. The method of any of Claims 1,2, or 13, wherein the polynucleotide encoding a desired trait or product is operatively linked to a cytokine-inducible promoter. WO 00/69257 PCT/USOO/13000 45
29. The method of any of Claims 1,2 or 13, wherein the polynucleotide encoding a desired trait or product is operatively linked to a tissue-specific promoter.
30. The method of any of Claims 1,2 or 13, wherein the polynucleotide encoding a desired trait or product is operatively linked to a developmentally or temporally regulated promoter.
31. The method of any of Claims 1, 2 or 13, wherein the gene encoding a genetic selection marker, and said gene is operatively linked to a constitutive promoter.
32. The method of any of Claims 1,2 or 13, wherein the polynucleotide encoding a desired trait or product is operatively linked to an exogenously inducible promoter.
33. The method of any of Claims 1, 2 or 13, wherein the polynucleotide comprises a gene encoding a genetic selection marker, and said gene is operatively linked to a tissue-specific promoter.
34. The method of any of Claims 1, 2 or 13, wherein the polynucleotide comprises a gene encoding a genetic selection marker, and said gene is operatively linked to a developmentally or temporally regulated promoter.
35. The method according to any of Claims 1, 2, or 13, wherein the vertebrate is a mammal or bird.
36. The method of Claim 35, wherein the mammal is selected from the group consisting of human and non-human primates, canines, felines, swine, mice, rats, gerbils, hamsters, rabbits, pachyderms, equines, ovines, porcines, bovines, and marine mammals.
37. The method according to Claims 35, wherein the bird is selected from the group consisting of ducks, geese, turkeys, chickens, ostriches, emus, guinea fowl, doves, and quail.
38. A non-human transgenic male vertebrate produced by the method according to any of Claims 1, 2 or 13, wherein the vertebrate comprises a native male germ cell carrying in its genome a polynucleotide of exogenous origin defining a gene encoding a desired trait or product, and the somatic cells in tissues outside the testis of said transgenic vertebrate lack the polynucleotide. WO 00/69257 PCT/USOO/13000 46
39. The non-human transgenic male vertebrate of Claim 38, wherein the vertebrate is a mammal selected from the group consisting of non-human primates, canines, felines, swine, mice, rats, gerbils, hamsters, rabbits, marine mammals, pachyderms, equines, ovines, porcines, and bovines, or a bird selected from the group consisting of ducks, geese, turkeys, chickens, ostriches, emus, guinea fowl, doves, and quail.
40. A non-human transgenic vertebrate produced by the method according to any of Claims 1, 2, or 13, wherein the vertebrate is the progeny of the male vertebrate, said progeny comprising one or more cells carrying in their genome a polynucleotide of exogenous origin encoding a desired trait or product.
41. The non-human transgenic vertebrate of Claim 40, wherein the vertebrate is a mammal selected from the group consisting of non-human primates, canines, felines, swine, mice, rats, gerbils, hamsters, rabbits, marine mammals, pachyderms, equines, ovines, porcines, and bovines, or a bird selected from the group consisting of ducks, geese, turkeys, chickens, ostriches, emus, guinea fowl, doves, and quail.
42. The non-human transgenic vertebrate of Claim 40, wherein the polynucleotide comprises a xenogeneic coding sequence.
43. The non-human transgenic vertebrate of Claim 40, wherein the polynucleotide comprises at least one biologically functional gene.
44. The non-human transgenic vertebrate of Claim 40, wherein the vertebrate comprises one or more cells expressing the genetic selection marker.
45. The non-human transgenic vertebrate of Claim 40, wherein the vertebrate is a male vertebrate.
46. A transgenic cell, wherein the cell is derived from the vertebrate of Claim40, said cell being a somatic cell.
47. A transgenic germ cell, wherein the cell is obtained from the vertebrate of Claim 40. WO 00/69257 PCTIUSOO/13000 47
48. The transgenic germ cell of Claim 47, wherein said cell is an ovum.
49. The transgenic germ cell of Claim 47, wherein said cell is a spermatozoan or precursor cell selected from the group consisting of spermatogonial stem cells, type B spermatogonia, primary spermatocytes, preleptotene spermatocytes, leptotene spermatocytes, zygotene spermatocytes, pachytene spermatocytes, secondary spermatocytes, and spermatids.
50. A transgenic male germ cell, wherein the cell is obtained from the male vertebrate of Claim 38.
51. A transgenic male germ cell, wherein the cell is obtained from the male vertebrate of Claim 45.
52. The transgenic germ cell of Claim 50 or Claim 51, wherein said cell is a spermatozoan or precursor thereof selected from the group consisting of spermatogonial stem cells, type B spermatogonia, primary spermatocytes, preleptotene spermatocytes, leptotene spermatocytes, zygotene spermatocytes, pachytene spermatocytes, secondary spermatocytes, and spermatids.
53. Vertebrate semen comprising a plurality of the transgenic germ cell of Claim 52.
54. A method of producing a non-human transgenic vertebrate animal line comprising native germ cells carrying in their genome at least one xenogeneic or allogeneic polynucleotide, said method comprising breeding of the vertebrate of Claim 40, with a member of the opposite sex of the same species; and selecting progeny for the presence of said polynucleotide.
55. The method of any of Claims 1, 2 or 13, wherein the polynucleotide encoding the desired trait or product is derived from a human.
56. The method of any of Claims 1, 2, or 13 wherein the genetic selection marker is a fluorescent protein or light-emitting protein.
57. The method of Claim 2, wherein support cells are co-administered to a testis along with isolated or selected germ cells. WO 00/69257 PCT/USOO/13000 48
58. The method of Claim 2, wherein genetically modified Leydig and/or Sertoli cells are isolated or selected, and co-administered to a testis of the recipient male vertebrate along with the isolated or selected germ cells.
59. The method of Claim 2, wherein the recipient male vertebrate's testis is substantially depopulated before the genetically modified germ cell is transferred thereto.
60. The method of Claim 2, wherein the recipient male vertebrate is the donor male vertebrate.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/311599 | 1999-05-13 | ||
US09/311,599 US6734338B1 (en) | 1997-11-14 | 1999-05-13 | Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies |
PCT/US2000/013000 WO2000069257A2 (en) | 1999-05-13 | 2000-05-12 | Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
Publications (2)
Publication Number | Publication Date |
---|---|
AU5268800A true AU5268800A (en) | 2000-12-05 |
AU781014B2 AU781014B2 (en) | 2005-04-28 |
Family
ID=23207612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU52688/00A Ceased AU781014B2 (en) | 1999-05-13 | 2000-05-12 | Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1190086A2 (en) |
JP (1) | JP2002543814A (en) |
AU (1) | AU781014B2 (en) |
CA (1) | CA2368620A1 (en) |
WO (1) | WO2000069257A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111713450A (en) * | 2020-05-26 | 2020-09-29 | 上海交通大学医学院 | Method for establishing PDX model of chronic granulocytic leukemia |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2814370B1 (en) * | 2000-09-22 | 2004-08-20 | Centre Nat Rech Scient | USE OF A NUCLEIC ACID / PEI COMPLEX FOR TARGETING STEM CELLS OF THE BRAIN |
EP1438401B1 (en) | 2001-09-18 | 2011-06-15 | Synageva BioPharma Corp. | Production of a transgenic avian by cytoplasmic injection |
US7550650B2 (en) | 2001-09-18 | 2009-06-23 | Synageva Biopharma Corp. | Production of a transgenic avian by cytoplasmic injection |
KR100569168B1 (en) * | 2003-08-08 | 2006-04-07 | (주)아비코아생명공학연구소 | Method for Culturing Avian Spermatogonial Stem Cells and Avian Spermatogonial Stem Cells Prepared thereby |
GB0325140D0 (en) * | 2003-10-28 | 2003-12-03 | Babraham Inst | Methods for selecting gametes and for producing genetically modified non-human animals |
JP2007275004A (en) * | 2006-04-10 | 2007-10-25 | Kaneka Corp | Method for producing gene recombinant birds by infection of lentivirus vector into spermary |
GB0802980D0 (en) * | 2008-02-19 | 2008-03-26 | Atazoa Ltd | Biological materials and uses thereof |
CA2895204C (en) | 2012-10-19 | 2022-06-28 | Trans Ova Genetics, L.C. | Methods for generating genetically superior animals |
US20140359796A1 (en) * | 2013-05-31 | 2014-12-04 | Recombinetics, Inc. | Genetically sterile animals |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8906214D0 (en) * | 1989-03-17 | 1989-05-04 | Nat Res Dev | Introducing an exogenous gene into birds |
JPH10304790A (en) * | 1995-09-29 | 1998-11-17 | Hoechst Japan Ltd | Formation of transgenic animal |
JPH09220039A (en) * | 1996-02-14 | 1997-08-26 | Chihiro Koike | Method for introducing external gene into sperm or ovum and producing method for transgenic animal |
ATE426036T1 (en) * | 1997-11-14 | 2009-04-15 | Cedars Sinai Medical Center | TRANSFECTION AND TRANSFER OF NON-HUMAN MALE GERM CELLS TO GENERATE TRANSGENIC NON-HUMAN MAMMALS |
EP1050586A4 (en) * | 1998-01-28 | 2003-07-23 | Takara Bio Inc | Method for transferring gene into germ cell |
WO1999040213A1 (en) * | 1998-02-09 | 1999-08-12 | Tranxenogen, Incorporated | Genetic manipulation of spermatogonia |
JP2003525581A (en) * | 1998-11-13 | 2003-09-02 | セダーシナイ メディカル センター | Vertebrate testis cell depopulating method and method for producing transgenic species |
CA2350829A1 (en) * | 1998-11-13 | 2000-05-25 | Cedars-Sinai Medical Center | Transfection of male germ cells for generation of selectable transgenic stem cells |
-
2000
- 2000-05-12 CA CA002368620A patent/CA2368620A1/en not_active Abandoned
- 2000-05-12 WO PCT/US2000/013000 patent/WO2000069257A2/en active IP Right Grant
- 2000-05-12 JP JP2000617726A patent/JP2002543814A/en active Pending
- 2000-05-12 AU AU52688/00A patent/AU781014B2/en not_active Ceased
- 2000-05-12 EP EP00937536A patent/EP1190086A2/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111713450A (en) * | 2020-05-26 | 2020-09-29 | 上海交通大学医学院 | Method for establishing PDX model of chronic granulocytic leukemia |
Also Published As
Publication number | Publication date |
---|---|
WO2000069257A2 (en) | 2000-11-23 |
EP1190086A2 (en) | 2002-03-27 |
AU781014B2 (en) | 2005-04-28 |
WO2000069257A3 (en) | 2001-08-09 |
CA2368620A1 (en) | 2000-11-23 |
JP2002543814A (en) | 2002-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU761758B2 (en) | Transfection and transfer of male germ cells for generation of transgenic species | |
US20080178311A1 (en) | Transfection, storage and transfer of male germ cells for generation of transgenic species & genetic therapies | |
US20020053092A1 (en) | Nucleic acid constructs containing a cyclin A1 promoter, and kit | |
US20140298504A1 (en) | Transgenic chickens with an inactivated endogenous gene locus | |
AU781014B2 (en) | Genetic modification of male germ cells for generation of transgenic species and genetic therapies | |
JP4226598B2 (en) | Method for in vitro proliferation of sperm stem cells, sperm stem cells grown using the method, and medium additive kit used for in vitro proliferation of sperm stem cells | |
CA2350829A1 (en) | Transfection of male germ cells for generation of selectable transgenic stem cells | |
WO2000029601A1 (en) | A method for depopulating of vertebrate testis and for generation of transgenic species | |
US6734338B1 (en) | Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies | |
US20050034177A1 (en) | Genetic modification of male germ cells for generation of transgenic species & genetic therapies | |
Kojima et al. | Gene transfer to sperm and testis: future prospects of gene therapy for male infertility | |
US8592643B2 (en) | Methods for introducing a human gene into a marmoset embryo for making a transgenic marmoset | |
Vishal et al. | Transgenesis: Embryo modification to sperm mediated gene transfer | |
JP2019103471A (en) | Gene-transfer vector for mammalian cells | |
Sato | Testis-and sperm-mediated Transgenesis: a review |